

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 543 195 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 92118598.9

(51) Int. Cl.<sup>5</sup>: **C12N 15/52, C12N 15/62,  
C12P 21/02, C07K 3/08,  
C07K 13/00, //C12N15/31**

(22) Date of filing: 30.10.92

(30) Priority: 31.10.91 US 784234

(43) Date of publication of application:  
26.05.93 Bulletin 93/21

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE**

(71) Applicant: **Dr. Karl Thomae GmbH**  
**Postfach 1755**  
**W-7950 Biberach 1(DE)**

(72) Inventor: **Entian, Karl-Dieter, Dr.**  
**Oberurseler Strasse 43**  
**W-6370 Oberursel/Ts. 5(DE)**  
Inventor: **Götz, Friedrich, Dr.**  
**Beim Herbstenhof 31**  
**W-7400 Tübingen(DE)**  
Inventor: **Schnell, Norbert, Dr.**  
**Seidmannsdorfer Strasse 148**  
**W-8630 Coburg(DE)**  
Inventor: **Augustin, Johannes, Dr.**  
**Viktor-Renner Strasse 59**  
**W-7400 Tübingen(DE)**

Inventor: **Engelke, Germar, Dr.**  
**Grüneburgweg 82**

**W-6000 Frankfurt/Main(DE)**  
Inventor: **Rosenstein, Ralf, Dr.**  
**Corinthstrasse 6**

**W-7410 Reutlingen 22(DE)**

Inventor: **Kaletta, Cortina, Dr.**  
**Seehauser Strasse 14**

**W-8000 München 70(DE)**

Inventor: **Klein, Cora, Dr.**

**Bernardstrasse 26**

**W-6050 Offenbach(DE)**

Inventor: **Wieland, Bernd, Dr.**

**Burkhardstrasse 34**

**W-7407 Rottenburg(DE)**

Inventor: **Kupke, Thomas, Dr.**

**Ludwigstrasse 12**

**W-7400 Tübingen(DE)**

Inventor: **Jung, Günther, Dr.**

**Ob der Grafenhalde 5**

**W-7400 Tübingen(DE)**

Inventor: **Kellner, Roland, Dr.**

**Tuchbleich-Strasse 12**

**W-6148 Heppenheim(DE)**

(54) **Biosynthetic process for the preparation of proteins.**

(57) A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described.

Also disclosed are recombinant DNA molecules which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.

**EP 0 543 195 A2**

Cross - Reference to Related Application

The present application is a continuation-in-part of U.S. Application Serial No. 07/353,590, the disclosure of which is fully incorporated by reference herein.

Field of the Invention

This invention relates to the biosynthesis of chemical compounds, and in particular to the biosynthesis of chemical compounds containing dehydroamino acid residues and/or thioether bridges. The invention also relates to the use of recombinant genetics to prepare enzymes involved in the biosynthesis of such chemical compounds.

Background of the Invention

Some polypeptide antibiotics such as nisin, subtilin, duramycin, cinnamycin, ancovenin, Ro 09 - 0198 and epidermin contain dehydroamino acids and lanthionine bridges. These polypeptides are produced by various respective strains of microorganism. Nisin for example can be produced by cultivating strains of *Streptococcus lactis*, and subtilin by cultivation of *Bacillus subtilis*.

The genetic basis for the biosynthesis of these antibiotics has not, hitherto, been elucidated. Thus, it has not been known, for example, whether biosynthesis of such antibiotics and, in particular, the formation of the unusual amino acids found therein occurs via ribosomal synthesis or via multi-enzyme complexes.

In addition it was not known whether the precursor proteins of such antibiotics were coded by distinct structural genes or were the degradation products of larger proteins.

In the course of work carried out to establish the structural gene of epidermin, we have been able to establish that surprisingly the above mentioned antibiotics, in particular epidermin, are each coded by a distinct structural gene, and that processing of a presequence polypeptide is carried out by an enzymatic complex which effects formation of dehydroamino residues and/or thioether bridges.

Furthermore, the multi-enzyme complex may be involved in the secretion of the protein through the cell membrane into the culture supernatant, as well as processing a prepolyptide. In this connection, such activity may be associated with a pre-sequence possessed by the pre-polypeptide, e.g., as in the case of the -30 to -1 sequence of pre-epidermin as described below.

Description of the Drawings

Figure 1 depicts the nucleotide sequence of the epidermin structural gene (epi A) and the deduced amino acid sequence of pre-epidermin. A Shine-Dalgarno sequence is boxed and the proteolytic cleavage site at which the propeptide is processed is indicated by an arrow. Inverted repeats are underlined and potential stop codons are noted as am (amber) and oc (ochre).

Figure 2A depicts a prediction plot for pre-epidermin using a Hyron program, in which the respective bar charts show: (a) flexibility; (b) hydropathy; (c) hydrophilicity; (d) propensities for turn; (e)  $\beta$ -sheet; and (f)  $\alpha$ -helix conformation.

Figure 2B depicts a helix wheel plot for pre-epidermin showing that the N-terminus may partially adopt an amphiphilic  $\alpha$ -helical conformation in an appropriate environment.

Figure 3 depicts a postulated naturation procedure for epidermin. The translated polypeptide (pre-epidermin) consists of 52-amino acid residues. Structure predictions indicate a partially  $\alpha$ -helical N-terminus from which residues -30 to -10 may form an amphiphilic  $\alpha$ -helix conformation. Water elimination occurs at the indicated Ser and Thr residues (a). With the exception of Thr<sup>14</sup>, water elimination is followed by sulphide ring formation (b) and at the C-terminus, decarboxylation (c) and double bond formation (d) to produce pro-epidermin. The pro-epidermin structure is then processed by proteolytic cleavage to produce epidermin.

Figure 4 depicts the structure of epidermin. The ring structures are designated as A, B, C, D and E. The structures of the amino acids mesolanthione and threo-methylanthione, are set forth.

Figure 5 depicts examples of unusual amino acids which are found in lanthione antibiotics and which can be formed in peptide products using the method of this invention.

Figure 6 depicts a schematic representation of the process for preparation of the pCUI plasmid from pCLP100 plasmid and pUC18 plasmid.

Figure 7 depicts the elution pattern of the isolated culture medium prepared in Example 2.

Figure 7B depicts the elution pattern of a standard containing gallidermin. Gallidermin is eluted at 7.54 minutes.

Figure 8 is a genetic analysis of episome pTü32 of *S. epidermidis* plasmid pTü32, including

8A: a restriction map of episome pTü32, and

5 8B: a restriction map of the 13.5 kb BglII fragment of pTü32. The filled arrow corresponds to the epiA structural gene. Open arrows represent reading frames epiB, C, D, P and Q.

8C: Southern hybridization of pTü32 digested with different restriction enzymes (EcoRI, EcoRV, BglIII, SphI) using a 15-mer oligonucleotide (5'-CACATCCAGGAGTAC-3') specific of epiA.

Figure 9 is a nucleotide sequence of the BglII/HpaI fragment of pTü32 containing reading frames epiA, B, C, D, P, Q, Y', and Y'' and the deduced amino acid sequences of the respective proteins. S/D sequences and termination structures are overlined. IR indicates inverted repeats. The start of the open reading frames of epiY, epiA, epiB, epiC, epiD, epiQ and epiP are indicated by bold letters. The N-terminal amino acid residues (possible translational start sites) are boxed.

Figure 10 shows the results of a Northern blot analysis of epiA (10A) and epiB (10B) expression in *S. epidermidis*, in which total RNA (40 µg, lanes 1, 3, and 5, or 20 µg, lanes 2, 4, and 6) were separated on 1.2% agarose gels and hybridization was performed with an antisense RNA probe (SP6 transcript. Filters were washed with increasing stringency; lanes 1, 2:1xSSC, 0.1% SDS, exposition time, 4 h, lanes 3, 4:0.5xSSC, 0.1% SDS, exposition time 16 h; lanes 5,6:0.1x SSC, 0.1% SDS, exposition time, 3 days). The positions of 235 and 165 RNAs were used as a size standards.

Figure 11 shows sequence homologies between EpiP and different serine proteases at the active sites (SUBSI, subtilisin I168 precursor of *B. subtilis* (Terzaghi *et al.*, *Appl. Microbiol.* 29: 807 - 813 (1975); major intracellular serine protease from *B. subtilis* (Maniatis *et al.*, *Molecular Cloning. A Laboratory Manual*; 2nd ed. Cold Spring Harbour Laboratory Press (1990); SUMYTV, thermitase from *Thermoactinomyces vulgaris* (Stahl *et al.*, *J. Bacteriol.* 158: 411 - 418 (1984)). The strongly conserved asparagine (asp), histidine (his), and serine (ser) residues are marked by asterisks. Similar amino acid residues are indicated by points and identical amino acid residues by colons.

Figure 12 shows sequence homologies between epiQ and PhoB (Makino *et al.*, *J. Mol. Biol.* 190:37 - 44 (1986)). Similar amino acid residues are indicated by points and identical amino acid residues by colons.

Figure 13 is a HPLC elution profile of epidermin which was produced in *S. carnosus* TM300.

30 13A: Elution profile of epidermin standard substance (6.75 min, indicated by an arrow).

13B: Elution profile of epidermin standard substance (6.75 min, indicated by an arrow) isolated from culture filtrates of *S. carnosus* TM300 pTepi14. Culture filtrates were adsorbed to XAD 1180, eluted with methanol and finally concentrated by evaporation.

35 13C: Elution profile of untransformed *S. carnosus* TM300 culture filtrate treated as in 13B. The solid line indicates the elution region of epidermin.

Figure 14 shows the construction of pT181mcs. The PvuII<sup>309</sup> - PvuII<sup>631</sup> fragment of pUC19, part of lacZ and the multiple cloning site (mcs), was inserted into the single NdeI site within pre of pT181 (Gennaro *et al.*, *J. Bacteriol.* 169:2601 - 2610 (1987); Kahn *et al.*, *Plasmid* 10:251 - 259 (1983)) by blunt-end ligation. lacZ is in the opposite orientation to a *pre*. Black bar, interrupted *pre*; open bar, inserted pUC19 fragment.

40 Figure 15 shows the construction of pCU1. PCLP100 is a derivative of pC194 (Horinouchi *et al.*, *J. Bacteriol.* 150:815 - 825 (1982)) containing a single PstI site which was generated by opening pC194 at the HindIII site, deleting the ends with Ba131 (approximately 950 bp) and inserting a PstI-linker by blunt-end ligation. PCU1 was then generated by blunt-end ligation of pCPL100 and pUC19 (Vieira *et al.*, *Gene* 19:259 - 268 (1982)) via the single PstI and NdeI sites, respectively. The multiple cloning site (mcs) in front of lacZ was used for cloning various epi gene-containing fragments. This shuttle vector replicates both in staphylococci and *E. coli*.

Figure 16 shows:

50 A) the generation of pTepi14 by cloning the 14 kb BglII fragment of pTü32 in pT181 mcs. This fragment containing the entire genetic information necessary for epidermin production in *S. carnosus*. The indicated ORFs and their transcriptional directions (indicated by arrows) are deduced from the DNA sequence. epiA, the structural gene, is presented by the black arrow.

B) various pTepi14 DNA fragments subcloned into pT181mcs (pT...) or pCU1 (pCU...). The respective plasmids were used to complement the *S. epidermidis* Epi mutants. The complete ORFs represent in the plasmid are indicated.

55 Figure 17 shows the construction of pPS4epiA and pPS4epiB. pPS4 is a derivative of pLipPS1 (Liebl *et al.*, *Mol. Gen. Genet.* 204:166 - 173 (1986)). A single BamHI site was inserted after a strong staphylococcal promoter. Cloning of genes into the BamHI site under the control of the ORF2 promoter normally leads to good expression in staphylococci. epiA was PCR-amplified and contained flanking BamHI sites. The 3.2 kb

BstNI fragment containing epiB was inserted into the BamHI site by blunt-end ligation. The respective EMS-mutants were complemented only when epiA and epiB were under the control of the ORF2 promoter. *lip*, lipase gene; *cat*, chloramphenicol acetyl transferase gene; ORF2, *S. carnosus*-specific truncated ORF.

Figure 18 shows the complementation of epidermin production in *S. carnosus* (pTepiABCDQ) by flanking DNA fragments. The fragments were subcloned into the compatible plasmid pCA44.

#### Description of the Preferred Embodiments

Broadly speaking the present invention provides in one aspect a bacterial host containing a plasmid, wherein said plasmid codes for a polypeptide which is not normally produced by said host, and wherein said host during cultivation provides a multi-enzyme complex whereby a polypeptide is produced which contains at least one dehydroamino acid and/or at least one lanthionine bridge, said produced polypeptide being foreign to said host.

A suitable multi enzyme complex is one which is capable of effecting at least one of the following operations, namely water elimination and sulphide bridge formation; the complex may also effect decarboxylation and double bond formation.

Suitable hosts for carrying out the process of the present invention are those which, without modification of their genetic material, are capable of producing polypeptides containing a dehydroamino acid residue and/or lanthionine bridge and/or a methyl lanthionine bridge. Examples of such hosts are *Streptococcus lactis*, *Bacillus subtilis*, *Streptomyces cinnamoneus*, *Streptomyces sp.* *Streptoverticillum griseover-ticillum*, *Staphylococcus epidermis*, *Staphylococcus epidermin* strain 5, *Staphylococcus gallinarum* and mutant strains thereof, e.g., a mutant strain of *S. epidermin* DSM 3095 which is incapable of producing epidermin.

Strains which are of special interest are *Staphylococcus gallinarum* (F16/P57) Tü 3928 which has been deposited with the Deutsche Sammlung von Microorganismen under the terms of the Budapest Treaty on 18 May 1988 and has received the depository number Tü 3928 in DSM 4616 and *Staphylococcus epidermis* DSM 3095 which was deposited by the present applicants with the Deutsche Sammlung von Microorganismen under the terms of the Budapest Treaty on 26th October 1984.

In order to transform a suitable host, a suitable plasmid may be modified by known genetic engineering techniques.

Desirably a plasmid from a host which produces a polypeptide containing at least one dehydroamino acid residue and/or at least one sulfide bridge is treated by modifying or replacing the gene coding for a pre-polypeptide to provide a plasmid coding for a polypeptide foreign to said host and then transforming said host with the altered plasmid.

Any of a variety of methods may be used to replace or modify a gene coding for the pre-polypeptide.

DNA coding for the pre-polypeptide sequence of the desired compound can be prepared by chemical synthesis. Suitable chemical syntheses have been disclosed in *Anal. Biochem.* 121, 365 (1982). The known techniques allow the preparation of polynucleotides, e.g., of up to 60 to 100 bases to be prepared.

Suitable protected nucleotides can be linked by the phosphotriester method Agarwal *et al.*, (*Agnew, Chem.* 84, 489 (1972)), the phosphotriester method (Reesem., *Tetrahedron* 39, 3, (1983)) or the phosphitetriester method (Letsinger *et al.*, *J. Am. Chem. Soc.* 98, 3655 (1976)) or the phosphoramidite method. The solid phase method allows for simplification of the synthesis of the polynucleotides.

The double stranded DNA can be constructed enzymatically from chemically prepared short but overlapping segments.

For example, overlapping polynucleotide sequences from both DNA strands can be used, which are held together in the correct conformation by base pairing and are then chemically linked by the enzyme DNA ligase (Khorana *et al.*, *J. Biol. Chem.* 251, 565 (1976)).

Another possibility comprises incubating in each case one polynucleotide sequence from the two DNA stands with a short overlapping segment in the presence of the four required deoxynucleoside triphosphates with a DNA-polymerase, for example, DNA-polymerase I, the Klenow fragment of polymerase I or T4 DNA-polymerase, or with reverse transcriptase. The two polynucleotide sequences are thereby held together in the correct arrangement by base pairing and are supplemented with the required nucleotides by the enzyme to give a complete double-strand DNA (Narany *et al.*, *Anal. Biochem.* 121, 365 (1982)).

Another suitable method for obtaining the DNA coding for a polypeptide comprises isolating the DNA from the genomic DNA of a tissue or cell culture or microorganism, lysing the cells e.g. with SDS or proteinase K, or if desired mechanically, and deproteinising the DNA by repeated extraction with phenol.

The RNA can be preferably digested with RNase. The obtained raw DNA is partially digested with suitable restriction enzymes e.g. HaeIII and A1uI and fragments isolated and multiplied in a suitable phage



or cosmid, e.g. in charon 4A or EMBL-3 phage and assayed for the desired sequences e.g. with a radioactively labelled DNA probe.

The DNA coding for a desired polypeptide can also be obtained by reverse transcription of isolated mRNA into cDNA. This may be the preferred method if the DNA structure is not known. In this method the DNA is obtained from genomic DNA in a cDNA library via the mRNA. The cDNA library comprises the genetic information which is complementary to the mRNA isolated from cells.

To obtain a cDNA library, the mRNA is isolated from cells expressing the desired basic (possibly unmodified) protein. This mRNA is converted into double stranded cDNA.

Standard methods well known in the art are applied in the preparation of mRNA. The cell membrane is broken and the cell content released from which the mRNA is isolated. The cell membrane is preferably broken by physical methods or lysis with detergents such as SDS, guanidine thiocyanate, definite salt conditions or homogenization, preferably by mixing. The mRNA is isolated by the standard methods of phenol extraction, ethanol precipitation, centrifugation and chromatography, preferably a combination of several methods. Centrifugation is preferably done over gradients, for example over a CsCl gradient. For chromatography, preferably columns are used, especially oligo-dT columns.

The total mRNA can be converted directly into Ds-cDNA following the methods of the art. Preferably the mRNA coding for a desired polypeptide is further enriched using several techniques, such as electrophoresis, chromatography and centrifugation, preferably sucrose gradient centrifugation.

Fractions containing mRNA coding for a desired polypeptide can be detected by various methods, such as *in vivo* or *in vitro* translations, followed by detection of a relevant activity or, when the nucleotide sequence is known, by hybridization with an oligonucleotide probe.

*In vivo* translation systems can be prokaryotic or eukaryotic systems. A preferred *in vivo* translation system is the *Xenopus laevis* oocyte system (see Maniatis *et al.*, *Molecular Cloning A Laboratory Manual Cold Spring Harbor Laboratory* (1982)). *In vitro* systems are, for example, wheat germ and rabbit reticulocyte lysates, both of which are commercially available.

From any pool of mRNA derived from unfractionated or fractionated mRNA, ds-cDNA can be obtained by the well known methods of the art (preferred general methods are described in Maniatis *et al.* (*supra*), Okayam and Berg, *Molecular and Cell Biology* 2, 161-170 (1982) and Heidecker, *Nucleic Acid Research* 11, 4891-4906 (1983)). In general, the mRNA is converted first to ss-cDNA using reverse transcriptase or DNA-polymerase I (Klenow fragment). Two methods are alternatively used for priming the synthesis of the ds-cDNA. The first method was the natural loop formation of the ss-cDNA. The second method is that of tailing the ss-cDNA with a homopolymeric tail such as poly-dC or poly-dT.

The mRNA fraction of which the corresponding polypeptide shows the highest activity in the detection system is transcribed into the complementary cDNA by methods well known in the art. The mRNA and oligo-dT as a primer are mixed, dNTPs are then added as starting material and the synthesis of the cDNA-mRNA hybrid molecule is realized by the enzyme reverse transcriptase. The RNA molecules are degraded by addition of NaOH. DNA polymerase is admixed, preferably the Klenow fragment of the DNA polymerase I, and the mixture is incubated at a suitable temperature, preferably 12-15°C. The mixture is incubated with nuclease S1 and the ds-cDNA corresponding to the mRNA coding for a desired polypeptide is obtained.

For amplification the obtained ds-cDNA can be spliced into suitable vector e.g. the plasmid pUC-KO and the obtained hybrid vector multiplied by use of a suitable host, e.g. *E. Coli* HB101. Reisolation of the hybrid vectors, and recovering the isolated cDNA therefrom allows a structure determination of the DNA coding for a desired polypeptide.

#### Preparation of a Hybrid Vector

A hybrid vector of the invention can be prepared by splicing a DNA coding for a polypeptide of the desired sequence into a suitable vector.

Suitable vectors are carriers for integrated passenger DNA, which can be used to transform a host microorganism.

Suitable as vectors are plasmids derived from microorganisms which in an untransformed state produce polypeptides which contain dehydroamino and/or sulfide groups. Suitable vectors carry the insert DNA at a defined position.

In general, such vectors may contain a replicon and a control sequence, i.e. a promoter, which are derived from the host cell or a species compatible with the host cell in which they are used. The vector ordinarily carries a replicon site and may contain sequences (marker genes) which are capable of providing phenotype selection in transformed cells. Suitable marker genes may provide antibiotic resistance or

resistance to heavy metals or they may complement a genetic defect of the host. Further useful sequences in such vectors are enhancer and activator sequences.

One suitable starting vector is a 54 Kbp plasmid pEpi32 from the strain *Staphylococcus epidermis* DSM 3095. This plasmid, which is characterized below, contains the *epiA* gene encoding for a 52 - prepeptide, which is processed to a tetracyclic 21 - peptide amide antibiotic. A vector carrying a passenger DNA is designated a hybrid vector.

The desired DNA is spliced into the starting vector by conventional methods.

A starting plasmid for example can first be linearised by a suitable restriction enzymes, e.g. the plasmid pEpi32 by HindIII, BamHI and EcoRI, then d/G-tailed in the presence of dGTP and the terminal deoxynucleotidyl transferase. The double stranded cDNA insert is dC-tailed in the presence of dCTP and terminal deoxynucleotidyl transferase. Combining both cDNA and vector results in the hybrid vector. Bacteriophages, such as lambda, are preferred for constructing genomic libraries. The lambda cloning systems are described by Maniatis (*supra*). The suitable vector DNA is digested to completion with the appropriate restriction enzyme, and the left and right arms are separated from the central fragments by velocity gradient centrifugation or gel electrophoresis. Another method is to digest parts of the stuffer fragments with restriction enzymes which lack recognition sites in the left and right arms. The isolated genomic DNA can be partially digested to fragments of 13 - 20kb in length. Afterwards the arms are ligated with the fragments of foreign DNA having termini compatible with those of the arms.

The appropriate DNA insert is recloned from the original vector used for the original cloning, into a suitable expression vector. To this end appropriate restriction enzymes are used, possibly in combination with oxonucleones, to produce the desired DNA fragments.

The DNA insert may be subcloned into a multiple site of a suitable well known plasmid vector e.g. derivatives of pC194, pTI81 and pUB110 at the restriction sites HindIII/BamHI/EcoRI.

The method of the invention can thus be used to prepare derivatives of known peptides and hormones, in which a cystein residue in the unmodified peptide is replaced by sulfide - bridged amino acids and serine and thiamine are replaced by corresponding dehydroamino acid residues.

These fragments are integrated into an appropriate expression vector by using the cohesive ends directly or by the addition of appropriate chemically synthesized oligonucleotide bridges. For the modification of the ends for example HindIII and BglII can be used. The method is not limited to any special restriction enzymes. Any desired link can be made between the expression vector and the DNA insert using suitable restriction enzymes in combination with chemically synthesized oligonucleotides.

Appropriate DNA inserts can also be obtained which code for polypeptide having site directed mutagenesis.

A variety of methods may be used to induce mutations of underlying DNA so as to prepare the desired mutants.

One method may comprise first inserting a fragment of a native or basic gene, containing sequences coding for the region to be mutated, into the replicative form of a phage, e.g. phage MI3mp8 to form MI3mp8PA. A synthetic oligonucleotide, complementary to the inserted sequences but containing one or more nucleotidetriplets which code for the amino acid to be substituted, is then annealed to the single stranded form of MI3mp8A to form a double stranded region. This region serves as a primer for DNA polymerase I synthesis of the remaining complementary strand. After replication and identification, the mutant sequence may be further modified or used to construct a suitable vector for expressing the mutated polypeptide.

In the work carried out on epidermin a wobbled DNA probe 5' - GTG(A)CAT(G/A)ATG(A)AAT(C)TT - 3' deduced from a suitable pentapeptide segment of the proposed pre - sequence of epidermin LysPhelleCylThr was prepared. This DNA probe was hybridized against plasmid DNA from *S. epidermin* DSM 3095.

Restriction analysis of the isolated plasmid reveals seven DNA fragments with EcoRI (16, 11, 10, 6.5, 5.5, 3.5 and 2.5 kbp), nine DNA fragments with HindIII (17, 14, 10, 5.3, 2.8, 1.8, 0.8, 0.6 and 0.5 kbp) and five DNA fragments with BamHI (20, 19, 10, 3 and 1 kbp).

A 5.4 kbp HindIII fragment was subcloned and subjected to rehybridization whereby the structure gene *epiA* was located within a 2.2 kbp EcoRI/BglII fragment.

As a mixture of 24 different 14 - mers was used as a hybridization probe. The probe was applied in a 30 - fold excess as a sequencing primer in accordance with the techniques described in Novick *et al.* *Ann. N.Y. Acad. Sci.* 182, 279 - 294 (1971), Southern, *J. Molec. Biol.* 98, 503 - 517 (1975) and Heinrich *et al.*, *Molecul. gen. Genet.* 209, 563 - 569 (1987). The peptide sequence of epidermin allowed identification of the open reading frame. A single methionine codon is in appropriate distance to a Shine - Dalgarno sequence. The structural gene of pre - epidermin terminates at the TAA stop codon, hence pre - epidermin

consists of 52 amino acids (Figure 1) and it is processed to the epidermin between Arg<sup>-1</sup> and Ile<sup>+1</sup>. Thus, as can clearly be seen, pre-epidermin is not a degradation product of a larger protein but is coded by a distinct structural gene.

Thus, it is apparent that, unexpectedly, the precursor protein of the antibiotics are coded by distinct structural genes.

A combination of prediction profiles for secondary structure ( $\alpha$ ,  $\beta$ , turns), flexibility, hydropathy, hydrophilicity (Figure 2A) and helix wheel plot were made using a Hycon program (Figure 2B). A high  $\alpha$ -helix probability is predicted for pre-epidermin -30 to -8 whereas the C-terminal part 1-22 which corresponds to pro-epidermin exhibits very high turn probability. Moreover, the prediction plot shows clearly, that the N-terminus -30 to -1 highly hydrophilic, whereas the C-terminal part is more lipophilic. The N-terminal part -30 to -8 seems to fold partially into an amphophilic  $\alpha$ -helix.

The N-terminal segment of pre-epidermin -30 to -1 does not contain any cysteine residues, whereas the C-terminal segment 1-22 contains the four cysteine residues involved in sulphide bridge formation. Sequence -30 to -1 included many cleavage sites for endoproteases whereas even in the pre-epidermin state, sequence 1-22 is highly resistant to proteolytic degradation.

The mature antibiotic can only be attacked by trypsin at Lys in position 13. The processing site Arg<sup>-1</sup> - Ile<sup>+1</sup> is hydrophilic and accessible, due to the turn forming Pro<sup>-2</sup> residue.

The various enzymatic reactions which occur in the production of the antibiotics such as epidermin include modifications of the propolypeptide part 1-22; cleavage of the N-terminal prepeptide fragment -30 to -1 and secretion of the matured antibiotic (see Figures 3 and 4).

The enzymatic modifications occur before cleavage of the prepeptide fragment. Enzymatic modification includes the elimination of water from Ser and Thr residues in position 5, 16, 19 and 8, 14 respectively to form dehydroalanine and dehydrobutyrine residues. Addition of thiol groups of Cys residues in position 2, 11, 21 and 22 to the C=C double bonds, also occurs, yielding the meso-lanthionine or (2S 3S, 6R)-3-methyl-lanthionine bridges. In addition, decarboxylation of residue 22 and double bond formation yields the C-terminal S-(2-aminovinyl)-D-cysteine. The reaction of C-terminally situated cysteine thiol groups with N-terminally located dehydroamino acids occurs with complete stereo-specificity in epidermin, nisin and subtilin. Accordingly, during modification these elimination-addition reaction imply a reversal of configuration of the C $\alpha$  carbon atoms at pre-epidermin residues L-Ser and L-Thr to give D-configured C $\alpha$  atoms. On the other hand, the L-configuration of the cysteine halves is still maintained.

The four sulphide rings are also formed, subsequently at the same catalytic site, which is supported by the interaction with the N-terminal amphophilic  $\alpha$ -helix. Only Thr<sup>+14</sup> dehydrates without finding a cysteine. This position (Lys<sup>+13</sup> - Dhb<sup>+14</sup>) constitutes the enzymatic cleavage site at which trypsin inactivates the antibiotic epidermin. During sulphide ring formation C-terminal rigidity and hydrophobicity increases and may favor interaction of pro-epidermin with the lipid bilayer and may induce translocation.

Finally, the hydrophilic  $\alpha$ -helical N-terminus -30 to -1 is cleaved by a specific protease at the characteristic cleavage site described above.

Using the techniques described above plasmids coding for lantibiotics can be modified either by mutation of the gene coding for the respective polypeptide or by replacement of such a gene by a gene coding for a different polypeptide and used to transform the original host or a different host, provided such host also, in its native state, is capable of expressing a lantibiotic.

Generally speaking, where the original functional gene codes for a pre-sequence, as discussed above for example in the case of epidermin, the DNA sequence coding for such a pre-sequence may be retained in the modified plasmid; in this case the DNA-sequence for the new, or mutated pro-polypeptide will be positioned directly upstream of the pre-sequence DNA similarly to the original pro-polypeptide sequence.

Cultivation of a bacterial host according to the present invention may be carried out under conventionally used cultivation conditions as described for instance in our co-pending British Patent Application No. 8811760.1 which was filed on 18th May 1988 and in European Patent Application Publication No. 0 181 578. Purification and isolation of the desired protein may also be carried out using the techniques or suitable modifications thereof described in the foregoing patent applications for epidermin and gallidermin, including the use of adsorbents, ion-exchange resins and if desired HPLC.

The process of the invention can be applied to the formation of novel compounds for experimental purposes, or to the formation of known compounds or derivatives of known compounds in new hosts. For instance a plasmid containing the gene coding for epidermin can be used to transform the species *Streptococcus lactis* to produce epidermin from that host, or the gene coding for Gallidermin (see our co-pending British Patent Application referred to above) can be used to replace the gene coding for the pro-polypeptide for epidermin in e.g. plasmid pEpi32 and used to transform *Staphylococcus epidermis* DSM 3095 to produce gallidermin from this host. Similarly other biologically active peptide derivatives



containing dehydroamino acid residues and/or lanthionine bridges and/or methyllanthionine bridges can be produced, such as derivatives of hormones such as human insulin, oxytocin, vasopressin, peptide antibiotics, hormone inhibitors such as elastase inhibitor and fibrinolytically active agents such as human tissue plasminogen activator. Such derivatives, as well as retaining biological activity of the parent compound can have increased stability and improved half-lives.

Ideally the DNA coding for the desired pro-polypeptide should include codons for cysteine and serine and/or for cysteine and threonine for the formation of thioether bridges.

For relatively short chain polypeptides these respective codons should normally be no more than eight and preferably no more than six codons apart, inclusive, although it is envisaged that, depending upon the steric conformation of the final polypeptide molecule much greater spacing is possible.

In respect of the formation of dehydroamino acids these will usually be derived from serine and threonine and, accordingly the DNA coding for the desired pro-polypeptide will include codons for such amino acids.

Amongst the unusual amino acids which may be present in a polypeptide produced according to the present invention are, dehydroalanine, 2,3-dehydro-2-aminobutyric acid, meso-lanthionine, (2S, 3S, 6R)-3methyl-lanthionine, S-(2-(Z)-aminovinyl)-D-cysteine, lysinoalanine and  $\beta$ -hydroxyaspartic acid; the structure of these residues are shown in Figure 5

We have unexpectedly found that the multi enzyme complex responsible for the posttranslational modification of pre-epidermin is located on the 54kb plasmid pTü32 of *Staphylococcus epidermis* Tü 3298/DSM 3095. Plasmid pTü32 is sometimes also referred to herein as pEpi32.

The six genes (ORFs) responsible for the production of epidermin are designated herein epi A, B, C, D, Q and P and are clustered within 8kb and the proteins for which they code are designated Epi A, B, C, D, Q and P respectively; epi A encodes the 52 amino acid-long preepidermin. As described below, epi B, C and D are involved in the four enzymatic modification reactions (i) water elimination by a serine/threonine dehydratase, (ii) sulfur addition by a lanthionine synthase, (iii) C-terminal decarboxylation by a cysteine decarboxylase and (iv) double bond formation. Epi P protein is believed to be responsible for cleaving the mature epidermin from the N-terminal leader peptide, based on its striking homologies with the essential domain of serine proteases (Koide *et al.*, *J. Bacteriol.* 167:110-116 (1986); Meloun *et al.*, *FEBS Lett.* 183:195-200 (1985); and Stahl *et al.*, *J. Bacteriol.* 158:411-418 (1984)) whilst Epi Q is believed to be a regulatory protein regulating epidermin biosynthesis, based on its distinct homology to the pho B gene of *E. coli* (Makino *et al.*, *J. Mol. Biol.* 190:37-44(1986)), the fact that both proteins are of a similar size with 205 (epi Q) and 229 (pho B) amino acid residues, the observed homology of 24.2% extending over the 153 C-terminal amino acid residues and the hydrophilicity plots of both proteins.

As a result of the unexpected finding of the entire genetic information for the epidermin biosynthesis and the elucidation of the genes for the proteins epi B, C, D, Q and P, it is now possible to obtain the isolated DNA coding for the proteins, and to construct plasmids containing one or more of these genes so that upon cultivation of a host containing such plasmids one of these proteins alone or predetermined combinations of the proteins may be expressed and subsequently isolated.

The present invention therefore includes DNA sequences encoding respectively for the protein Epi B or Epi C, or Epi D, or Epi P or Epi Q. These sequences may be isolated DNA either single or double stranded, obtained by cleavage of and isolation from pTü32 in known manner or obtained by chemical synthesis or any other conventional procedure. The DNA may also be integrated in a plasmid, suitably an expression plasmid and under the control of a promoter regulator; such constructs when transformed into a suitable host which is then cultivated will express the protein Epi B, Epi C, Epi D, Epi P or Epi Q or combination of these proteins according to which DNAs were ligated into the plasmid. Alternatively plasmid pTü32 may be treated with suitable restriction nucleases to excise one or other of the DNA sequences, followed by religation after any necessary modification of the free ends of the digested plasmid, so as to create a modified plasmid containing DNA sequences coding for predetermined ones of epi B, C, D, P and Q.

A further variant comprises the substitution of the gene coding for epidermin in pTü32 with a DNA sequence coding for a predetermined amino acid sequence whereby cultivation of a suitable host with the modified plasmid will result in expression of a protein different from epidermin.

It is thus possible to substitute a DNA sequence encoding for gallidermin or mutant epidermin or other lantibiotic or other protein, for the epidermin coding sequence in pTü32 whereby the resulting plasmid can be transformed into a suitable host which may be a host normally incapable of producing a lantibiotic or any of the proteins Epi B, C, D, P or Q and to cultivate the host under conditions whereby the substituted DNA sequence and the genes epi B, C, D, P and Q are expressed, so as to obtain a protein which is gallidermin, mutant epidermin or other protein containing at least one structural feature of a lantibiotic.



Alternatively the genes coding for the proteins Epi B, C, D, P or Q may be inserted into a suitable vector, together with a DNA sequence encoding a predetermined amino acid sequence, the genes coding for the Epi proteins and the predetermined amino acid sequence being operably connected with suitable promoter regulator functions, the resulting plasmid being transformed into a suitable host which may be a host normally incapable of producing a lantibiotic or any of the proteins Epi B, C, D, P or Q, and the host cultivated so that the inserted genes cause the expression of a protein derived from said predetermined amino acid sequence but containing a lantibiotic structural feature, which protein may be gallidermin, epidermin, mutant epidermin, or another protein.

The present invention thus also includes within its scope DNA sequences capable of hybridizing, preferably under stringent conditions, with the DNA sequences described herein and coding for proteins having substantially the activity of the proteins Epi B, C, D, P or Q. Stringent hybridization conditions select for DNA sequences of greater than 85% or, more preferably, greater than about 90% homology. Screening of the cDNA library may be carried out under highly stringent conditions according to the method described in European Patent Application No. 88 119 602.9 and Kashima et al. (*Nature* 313:402-404 (1985)). The DNA sequences capable of hybridizing under stringent conditions with the DNA sequences disclosed in the present application may be, for example, allelic variants of the disclosed DNA sequences, may be naturally present in the particular microorganism but related to the disclosed DNA sequences, or may be derived from other sources. General techniques of nucleic acid hybridization are disclosed by Maniatis, T. et al., In: *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor, NY (1982), and by Haymes, B.D. et al., In: *Nucleic Acid Hybridization, a Practical Approach*, IRL Press, Washington, DC (1985), which references are herein incorporated by reference. The proteins Epi B, C, D, P and Q are valuable and interesting new reagents potentially useful in the preparation of novel proteins or other substances containing structural features such as dehydroalanine, dehydrobutyrine, meso-lanthionine, 3-methyl-lanthione, and S-(2-aminovinyl)-D-cysteine.

As such, they may be utilized as isolated proteins, or as chemical catalytic reagents in chemical synthesis procedures to investigate the extracellular processing of proteins by such enzymes.

The invention also relates to the proteins Epi B, C, D, P and Q in substantially pure form. By the term "substantially pure" is intended that the protein is free of the impurities that are naturally associated therewith. Substantial purity may be evidenced by a single band by electrophoresis.

The polypeptides of the invention may be isolated and purified from the above-described recombinant molecules in accordance with conventional methods, such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, or the like. Preferably, the polypeptides are produced as part of a fusion protein which further comprises an auxiliary protein. Such auxiliary which facilitates the isolation and purification of the polypeptide of interest. Such auxiliary proteins include, for example, typical secretion signals, the maltose binding protein from *E. coli*, or protein A. Methods for preparing fusion proteins comprising protein A, the purification thereof by immunoaffinity chromatography, and the cleavage thereof to release the protein of interest is taught, for example, in PCT Application Publication No. WO84/03103 (1984).

A necessary condition to permit cleavage of the fusion protein is that it contains a unique cleavage site which may be recognized and cleaved by suitable means. Such a cleavage site may be a unique amino acid sequence recognizable by chemical or enzymatic means and located between the desired protein and the auxiliary protein. Such a specific amino acid sequence must not occur within the desired protein or auxiliary protein. Examples of enzymatic reagents include proteases such as collagenase which may recognize the amino acid sequence  $\text{NH}_2 - \text{Pro} - \text{X} - \text{Gly} - \text{Pro} - \text{COOH}$ , wherein X is an arbitrary amino acid residue, e.g. leucine; chymosin (rennin) which cleaves the Met-Phe bond; kallikrein B which cleaves on the carboxyl side of Arg in  $\text{X} - \text{Phe} - \text{Arg} - \text{Y}$ ; enterokinase which recognizes the sequence  $\text{X} - (\text{Asp})_n - \text{Lys} - \text{Y}$ , wherein  $n = 2 - 4$ , and cleaves it on the carboxyl side of Lys; thrombin which cleaves at specific arginyl bonds. Examples of chemical agents which may be used to cleave the fusion proteins include cyanogen bromide which cleaves after Met; hydroxylamine which cleaves the Asn-Z bond wherein Z may be Gly, Leu or Ala; formic acid which in high concentration (~70%) specifically cleaves Asp-Pro.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

## EXAMPLES

## Example 1

5 1. Overproduction of gallidermin

A DNA fragment containing the open reading frame of gallidermin can be cloned in *Staphylococcus epidermidis* DSM 3095, the epidermin producing strain by using a medium copy plasmid such as pC194, pE194, pUB110, pT181 or pMK148 gallidermin. An increase of the gene doses usually correlates with an  
 10 increase of product production; the correlation is not necessarily linear. High copy number plasmid derivatives of pC194 or pT181 can be used as cloning vehicles too.

2. Exchange of leader sequence

15 The leader - sequence of epidermin corresponding to amino acids - 1 to - 30, is involved in the secretion of epidermin. The sequence can be used to secrete other peptides in *S. epidermidis* such as gallidermin.

The leader - sequence DNA can be made portable by inserting respective linkers at the beginning and at the end of its sequence. Thus the leader sequence DNA can be isolated in large amounts from the  
 20 plasmid and can be inserted at respective positions of other peptides and proteins. The leader - sequence DNA can also be produced by chemical synthesis.

## Example 2

25 Production of Gallidermin using *S. epidermis* as host1. Preparation of plasmid (see Figure 6)

30 a) Plasmid pCUI was prepared by ligating Pst1 digested pCLP100 and Nde1 digested pUC18 using Klenow as described in the thesis "Molekular genetische Untersuchungen zur plasmidkodierte Arsenit und Arsenatrestistent bei Staphylococcen", by Dr. Ralf Rosenstein (available from the Technische Universität, Munich, West Germany). The resulting plasmid was then digested with EcoR1.

b) Chromosomal DNA was isolated from *S. gallinarum* (DMS 4616) and was digested with EcoR1. A 4.7 kb fragment containing the gallidermin structural gene in a 2.4 kb long sequence between HindIII and  
 35 EcoR1 restriction sites was isolated using as a primer the sequence.

5' CAC ATC CAG GAG TAC 3'

c) The 4.7 kb Fragment was then ligated into the EcoR1 site of the digested pCUI plasmid from step a) to give a plasmid designated pCUgdm1.

40 2. Preparation of a *S. epidermis* host

In this example a mutant strain of *S. epidermis* DSM 3095 incapable of producing epidermin was isolated.

45 The mutagenesis was carried out on a strain which was characterized by chromosomally coded Rifampicin resistance (20 ug/ml).

*S. epidermis* DSM 3095 grown on Agar plates was used to inoculate 30 ml basic broth medium which was cultivated overnight. 0.5 ml of the overnight cultivation was then used to inoculate 50 ml of production medium which was shake cultivated at 37 ° C for three hours.

50 Cells were removed from the cultivation medium and suspended in 4.5 ml pre - warmed TM - Buffer (30 mM Tris - Maleate pH 6.5 (the resulting solution is designated Solution A)).

The solution A was checked for spontaneous mutations and for cell count ( $1.25 \times 10^{10}$  cells/ml).

4 ml of solution A was thoroughly shaken with 1 ml ethyl methyl sulphonate (final concentration 47 µg/ml) and then maintained under shaking at 37 ° C for one hour.

55 Cells were then extracted from the cultivation broth, washed twice in TM - Buffer and resuspended in 5 ml TM - Buffer (the resulting solution was designated Solution B and contained mutated cells).

Solution B was found to contain  $2 \times 10^8$  cells/ml which corresponds to survival rate of 1.6%.

50 ml of solution B was added to 5 ml production medium and grown overnight at 37 ° C (phenotypic expression). The resulting solution was designated Solution C. A cell count showed  $7.3 \times 10^8$  cells/ml.

The solution was plated on BM - Agar plates and individual colonies were picked out. These were used to inoculate test plates (consisting of BM - Agar to which *Micrococcus luteus* has been laid on the surface). Those colonies which had no inhibitory effect on *M. luteus* were selected as non - producers of Epidermin.

- 5 BM Agar contains per liter:  
 10 gm Peptone No. 140  
 5 gm Yeast extract  
 1 mg Glucose  
 5 mg NaCl  
 10 1 mg  $K_2HPO_4$   
 pH 7.5

A mutation rate of about 3% was noted.

The 45 non - producers which were found were sub - cloned 20 times to yield 16 stable non - producers.

- 15 All stable non - producers were found to contain the wild type plasmid pEpi32. From the restriction pattern this is identified as identical to the plasmid in the wild type strain.

#### Transformation of non - producing *S. epidermis*

- 20 750 ml of BM - medium was inoculated with 5 ml of medium obtained by overnight cultivation of a stable non - producing strain, and the inoculated medium was shake cultivated in a 2 liter flask at 37° C with a shake speed of 120 rpm.

- The initial optical density of the inoculated BM - medium was 0.03 - 0.04. When the optical density had reached 0.45 - 0.55 the cells were removed by centrifugation in a GS. - 3 - Rotor at 8500 rpm for 15 minutes at 4° C. The isolated cells were then washed successively in 750, 350, 40 and 10 ml of 10% glycerin, suspended in 2 - 3 ml 10% glycerin, and frozen in 110 ml portions in ERGs at - 70° C. The cell count amounted to  $1 - 5 \times 10^{10}$ /ml.

The frozen cells were thawed at room temperature for 5 minutes, then 50  $\mu$ l of cell suspension was incubated in an ERG with 2  $\mu$ l plasmid pCUgdm1 in TE - Buffer for 30 minutes at room temperature.

- 30 The mixture was then introduced into an electroporation cuvette having a 0.2 cm electrode gap and immediately electroporated. Thereafter the cells were rapidly resuspended in 950  $\mu$ l SMMP50 - medium, transferred into a 2.5 ml ERG and shaken for 90 minutes at 37° C. The ERGs were inclined at 45° in order to provide for a good aeration of the medium.

- 35 SMMP50 - medium contains pro 100 ml, 55 ml 2SMM, 40 ml 4 PAB and 5 mol 5% BSA. The 2SMM contains 1 mol saccharose, 0.04 mol maleic acid, 0.04 mol  $MgCl_2$  and NaOH to pH 6.5. 4 PAB is a solution of 7 g/100 ml of Gibco antibiotic medium 3.

The cell suspension is diluted and spread on a BM - Agar containing gallidermin which is incubated for 20 hours at 37° C.

- 40 Testing of growing strains which produce gallidermin was carried out by selection of colonies from a *M. luteus* test plate and by cultivating the respective selected colonies and determining the presence of gallidermin by HPLC.

Three pCUgdm1 transformed mutants capable of producing gallidermin were located.

#### Determination of the presence of gallidermin produced by pCUgdm1 transformed *S. epidermin*

- 45 a) Bio assay

- 50 FP - Agar was inoculated with *M. luteus* ATCC 9341 and incubated at 37° C for 18 hours. Half of the produced culture was removed with a loop and suspended in 100 ml FP - medium and was cultivated for 8 hours at 36° C. The cultivation was stopped when the optical density reached 1.0. FP - Agar was inoculated with 0.5% of this suspension, each 10 ml was poured into a Petri dish and stored for 3 weeks at 4° C.

- 55 The Plate diffusion test was carried out as described in Zähler and Maas, "Biology of Antibiotics", Springer Verlag, Berlin 1972. 10  $\mu$ l of culture filtrate from cultivation of the transformed *S. epidermin* was captured on a filter paper and dried. The paper was placed on the test plate which was then incubated for 24 hours at 37° C.



b) HPLC

The selected transformed strain was cultivated for 26 hours in the production medium. The culture broth was centrifuged for 10 minutes at 13.000 rpm.

The isolated culture liquid was then subject to HPLC on a SP 8.700 liquid chromatography apparatus (Spectra Physics, Darmstadt, FRG) using as the mobile phase A) H<sub>2</sub>O with 0.5% 70% perchloric acid and B) Acetonitrile. Column packings were Nucleosil - 100 C - 18 of grain size 7  $\mu$ m and column sizes 125 mm x 4.6 mm I.D. and 20 mm x 4.6 mm ID for the pre - column.

Gradients were as follows:

time (min.)	A [%]	B [%]
0	77.5	22.5
8	63.0	37.0
8.5	0	100
9.5	0	100
10	77.5	22.5
14	77.5	22.5

The resulting chromatogram is shown in Figure 7A. A standard curve is shown in Figure 7B showing that gallidermin elutes at 7.54 minutes.

The following were used as culture medium.

1. FP - Agar	
Meat extract	4 g
Peptone	10 g
NaCl	3 g
Na <sub>2</sub> HPO <sub>4</sub>	5 g
Glucose	10 g
Complex agar	15 g
Water	1 liter
pH	7.2

2. FP - Medium	
Meat extract	4 g
Peptone	10 g
NaCl	3 g
Na <sub>2</sub> HPO <sub>4</sub>	5 g
Glucose	10 g
Water	1 liter
pH	7.2

3. Production medium	
Meat extract	33 g
Malt extract	30 g
NaCl	40 g
Calcium Hydroxide	3.8 g
Water	1 liter
pH	6.5

Example 3Plasmid Isolation

5 Plasmid DNA from *S. epidermis* Tü3298 was isolated according to a modified procedure of Norick *et al.*, *Ann. NY-Acad. Sci.* 182:279-294 (1971). *S. epidermis* was grown on BM-media (1% peptone 140, Gibco, Neu-Isenburg, F.R.G., 0.5% yeast extract, Difco, Detroit, USA, 0.1% glucose, 0.5% NaCl and 0.1%  $K_2HPO_4 \times 2H_2O$ ) until stationary phase. Cells were centrifuged and washed twice with 0.5 M EDTA. The pellet was resuspended in 80 ml NaCl buffer (50 mM Tris/HCl, pH 7, 50 mM EDTA, 2.5 M NaCl), 1.5 ml  
 10 lysostaphin solution (0.5 mg/ml, Sigma, Heidelberg, F.R.G.) was added and the suspension was incubated at 37°C for 20 min. Cells were lysed by the addition of 80 ml lysis buffer (50 mM Tris/HCl, pH 8, 300 mM EDTA, 500 mM Brij., 40 mM sodium deoxycholate and kept on ice for 1 h. The lysate was centrifuged (30 min, 13,000 rpm, 4°C) and the supernatant was mixed with one quarter of its volume with 50% solution of PEG-6000. Plasmid DNA was precipitated at 4°C overnight. The DNA suspension was centrifuged (20  
 15 min, 13,000 rpm, 4°C), resuspended in 8 ml TE buffer and 50 µl of proteinase K solution (20 mg/ml) was added. After incubation at 37°C for 15 min the DNA was precipitated with ethanol and further purified by CsCl centrifugation (1 g CsCl/ml, 40,000 rpm, 40 h, 20°C).

RNA isolation and electrophoreses

20 *S. epidermin* was grown on SMS minimum medium (Terzaghi *et al.*, *Appl. Microbiol.* 29:807-813 (1975)) and RNA isolated therefrom, using a modified procedure similar to that described for *Bacillus subtilis* RNA (Ulmanen *et al.*, *J. Bacteriol.* 162:176-182 (1985)). Cells were lysed with lysostaphin (0.1 mg/ml) in protoplasting buffer and incubation was performed at 37°C. Total RNA was glyoxylated (McMaster *et al.*,  
 25 *Proc. Natl. Acad. Sci. USA* 74:4835-4839 (1977)) and separated on a 1.2% agarose gel using 10 mM  $Na_2PO_4$ , pH 7, as electrophoresis buffer. RNA was stained with ethidium bromide and blotted to a nitrocellulose membrane (Scheider and Schuell, Dassel, F.R.G.) by capillary transfer with 20xSSC buffer (0.15 M NaCl, 0.015 M tri sodium citrate, pH 9). 23SrRNA and 16SrRNA were used as size standards.

In vitro transcription

30 Single stranded RNA probes were obtained by cloning the respective fragment in a pSPT18/19 vector system (Boehringer Mannheim, Mannheim, F.R.G.). The plasmids were linearized with EcoRI or HindIII to get a linear DNA template. For transcription the protocol in Melton *et al.*, *Nucl. Acid Res.* 12:7035-7056  
 35 (1984), was modified according to the instructions of the commercial supplier. T7-RNA polymerase or SP6-RNA polymerase was used in the presence of  $\alpha^{32}P$ -CTP (800 Ci/mMol). Unincorporated ribonucleotides were separated from labeled RNA by Sephadex G50 chromatography.

Northern hybridization

40 RNA was transferred after electrophoresis according to Thomas, P.S., *Proc. Natl. Acad. Sci. USA* 77: 5201-5205 (1980). After 2 h incubation at 80°C the filter was shortly incubated in 20 Tris/HCl, pH 8, at 100°C to reverse glyoxylation. Afterwards filters were prehybridized at 42°C in 50% formamide, 5xSSC (0.15 M NaCl, 0.015 M tri sodium citrate, pH 9), 50  $NaPO_4$ , pH 6.5, 0.1% ficoll 400 (Pharmazia, Freiburg,  
 45 F.R.G.), 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin and 0.25 mg/ml denatured salmon sperm DNA for 2h. After probe addition hybridization was performed in the same buffer at 42°C for 12 h. Filters were washed once in 1xSSC, 0.1% SDS at 42°C for 15 min and exposed to Kodak-X Omat films at -70°C for 4 h. Thereafter filters were washed twice with 0.5 SSC, 0.1% SDS at 70°C for 15 min and autoradiograms were exposed at -70°C for 16 h. Next day washing was continued with 0.1xSSC, 0.1%  
 50 SDS at 70°C for 30-60 min and afterwards again exposed to Kodak-X Omat films at -70°C for 3 days.

Southern hybridization

For southern hybridization (Southern, E.M., *J. Mol. Biol.* 98:503-517 (1975)) 5' labeled oligonucleotides  
 55 were used as probes at 23°C. Oligonucleotides were labeled with gamma $^{32}P$ -ATP using 4T polynucleotide kinase (Boehringer Mannheim, Mannheim, F.R.G.). Oligonucleotides and primers were synthesized on a 391 DNA synthesizer (Applied Biosystems, Weiterstadt, F.R.G.) and used without further purification.

### DNA sequencing

DNA was sequenced radioactively and non-radioactively by the chain termination method (Sanger *et al.*, *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977)) using T7-DNA polymerase (Pharmazia, Freiburg, F.R.G.). Radioactive plasmid sequencing was performed as described in Hattori *et al.*, *Anal. Biochem.* 152:232-238(1984) with appropriate primers. The 3.6 kb BamHI/PstI fragment was sequenced non-radioactively on an Applied 373A DNA sequenator (Applied Biosystems, Weiterstadt, F.R.G.). The respective fragment was cloned in phagemid pBSK-/+ . The construction was digested with BamHI and SacI and the linearized DNA was unidirectionally digested from the 5' end with exonuclease III (Boehringer Mannheim, Mannheim, F.R.G.) to obtain a set of nested deletions which were treated with mung bean nuclease (Boehringer Mannheim, Mannheim, F.R.G.) to receive blunt ends. After electrophoresis (1% agarose gel) fragments of appropriate size were isolated from the gel, religated and transformed into *E. coli* strain XL-1 Blue. Single stranded DNA was isolated by using helper phage CSM13 and sequenced with Taq Polymerase (Promega, Freiburg, F.R.G.) according to the protocol of the commercial supplier.

### Plasmid Construction

The staphylococcal tetracycline resistance plasmid pT18I has been sequenced (Kahn *et al.*, *Plasmid* 10:251-259 (1983)) and found to contain a single NdeI site within the pre-gene which is not necessary for plasmid replication (Gennaro *et al.*, *J. Bacteriol.* 169:2601-2610 (1987)). The multiple cloning site (mcs) of the *E. coli* vector pUC19 (Yanisch-Perron *et al.*, *Gene* 33:103-119 (1985)) was inserted into the NdeI site to form pT18Imcs (see Figure 14).

A staphylococcus-*E. coli* shuttle vector, pCUI (Figure 10) was constructed from pCLP100, a derivative of the staphylococcal chloramphenicol resistance plasmid pC194 (Horinouchi *et al.*, *J. Bacteriol.* 150:815-825 (1982)) and the *E. coli* vector pUC19. PCUI is stably maintained in both hosts with an insert size up to approximately 6 kb. pT18Imcs and pCUI are compatible in staphylococci and were used to subclone DNA fragments from pTü32.

A HindIII fragment of pTü32 was cloned in pUC19 and used as a probe in Southern hybridization to identify further restriction sites near the HindIII fragment (Figure 8C).

The 13.5 kbp BglII fragment of the 54 kbp episomal element pTü32 from *S. epidermis* was subcloned in pT18Imcs to yield pTepi4 (Figure 8A). For DNA sequencing subclones were made in the *E. coli* vector pUC19 (Yanisch-Perron *et al.*, *Gene* 33:103-119 (1985)) and pBluescript II<sup>R</sup> (Stratagene, Heidelberg, F.R.G.). Single stranded RNA probes were obtained from DNA cloned in vector pSPT18/19 (Boehringer Mannheim, Mannheim, F.R.G.).

### Gene Analysis

Sequencing the DNA region adjacent to the epidermin structural gene, epi A, revealed five additional complete open reading frames epi B, C, D, P and Q inside the 13.5kbp BglII fragment of pTü32.

As can be seen in Figure 9, directly adjacent to the sequence encoding for EpiA separated by only 50 nucleotides from the epiA ochre codon there is a large open reading frame preceded by a S/D sequence which spans 2,970 bp. A TTG codon for leucine which can also act as a translation start codon in staphylococci is in appropriate distance (86p) to a S/D sequence. This open reading frame is designated epiB and as described herein can successfully be used for the complementation of epidermin biosynthesis mutants and an essential role in epidermin biosynthesis.

The protein coded for by epiB, starting from the TTG (Leu) has a molecular weight of about 115kDa, a net charge of -3 at pH7, and is moderately hydrophobic (41% hydrophobic residues) as may also be predicted from a hydrophilicity plot according to Kyte *et al.*, *J. Mol. Biol.* 157:105-132 (1982).

At the 3' end of epiB no palindromine structure characteristic of transcription termination can be seen. There is, however, a 122bp overlap with an other reading frame epiC, shifted by -1 base pair also to be seen in Figure 9.

We have established this to be no artefact by independently cloning and sequencing the respective 47 kbp HindIII-fragment twice from two independent plasmid isolations. This was also confirmed by mutant complementation with an epiC containing fragment as described herein.

Inside the overlapping region of epiB and epiC reading frames the first TTG codon (Leu) which is only 36bp 3' to an AGGA element serves as a translational start codon, indicating that both reading frames overlap by about 40 codons. The actual amino-terminus of the EpiC protein was determined by N-terminal sequencing. Reading frame epiC encodes a protein with 445 amino acid residues commencing with



starting codon TTG (Leu). The reading frame epiD directly follows 3' to epiC with a start ATG 86p 3' to a AGGAGG S/D sequence. 3' to epiD is a classical rho dependent transcription terminator structure; epiD encodes a protein of 181 amino acid residues with ATG (Met) on start codon.

None of the proteins EpiB, C, D, P and Q show any similarity with protein sequences filed in the protein data bases Swiss Prot and Gene Bank, and thus represent unknown types of enzymes and regulatory proteins.

#### Transcription of the biosynthetic genes

Single stranded RNA probes were obtained by cloning the desired fragment in a pSPT 18/19 vector system (Boehringer Mannheim, Mannheim, F.R.G.) as described above.

Two transcripts differing considerably in size were obtained as illustrated in Figure 10. A hybridization probe specific of epiA identified a small transcript of about 300bp. Transcripts of similar size were also found for the lantibiotics nisin (Buchmann *et al.*, *J. Biol. Chem.* 263:16260 – 16266 (1988)) and subtilin (Banerjee *et al.*, *J. Biol. Chem.* 263:9508 – 9514 (1988)). Additionally a large transcript of approximately 5kb can be identified with a hybridization probe specific for epiB. As there were no *E. coli*-like promoter sequences in front of epiB, whereas appropriate sequences were located 5' to epiA it can be seen that the epiA promoter acts as a promoter for a polycistronic mRNA.

#### Downstream open reading frames

The open reading frames epiP and epiQ are located on the opposite DNA to epiB, C and D with epiQ sharing a termination structure with epiD a perfect hairpin with a 6bp loop.

Exactly within this loop structure the TAA stop codons for both reading frames epiD and epiQ share two of three nucleotides.

The epiP reading frame starts with an ATG codon which is in appropriate distance (6 bp) to a S/D sequence. Taking the ATG codon as the translational start of epiP a protein of 461 amino acid residues with molecular weight of 51.8kD. epiP shares characteristic homologies with the conserved amino acid motives of serine proteases (see Figure 11) indicating that epiP is implicated in cleaving the mature lantibiotic from the modified prepeptide.

The epiQ reading frame also starts with an ATG codon and encodes 205 amino acid residues (Figure 9). A S/D sequence is present 6 bp distance to the ATG codon and a molecular weight of 243 kD can be deduced from the DNA sequence. The epiQ protein shares characteristic homologies with PhoB (see Figure 12) which is a positive regulatory factor for the phosphate regulatory of *E. coli* so that epiQ is implicated as a regulatory factor in lantibiotic synthesis.

Preceding epiP is an *E. coli*-like -10 region (5' - TATAAA) 12bp in front of the S/D sequence which may serve as a promoter in staphylococci. The distance between the epiP stop codon and the ATG start codon of epiQ is only 10 nucleotides and the epiQ S/D sequence overlaps with the epiP termination codon as shown in Figure 9.

5' to epiA, B, C, D a further reading frame with opposite orientation can be seen which potentially encodes a maximum of 148 amino acids. A characteristic S/D sequence is present but none of the previously described start codons for staphylococci (ATG, TTG, GTG). With a -1 frame shift a further reading frame follows which exceeds the isolated BglII fragment illustrated in Figure 9.

These two reading frames are homologous to a single open reading frame, gdm Y, identified adjacent to the structural gene of gallidermin (Schnell, N., *Biosynthese der Peptid-Antibiotika Epidermin und Gallidermin*; Doctoral Thesis, University of Tübingen, F.R.G. (1989)). The homologous reading frames on the *S. epidermis* plasmid are designated epiY' and epiY''.

#### Example 4

*S. carnosus* TM300 was transformed with the plasmid pTepil4, prepared as described above, using standard techniques. The transformed strain was then grown on BM - media (see above).

The resulting transformants were found to be capable of inhibiting the epidermin sensitive tester strain *Micrococcus luteus* ATCC9341. In this assay 1 ml of an overnight culture of *M. luteus* (adjusted to an OD<sub>573</sub> of 1.0) was added to 500 ml molten BM - Agar. Petri dishes usually contained 10 ml of this agar. Dilutions of *S. epidermis* cultures were spread on the agar surface. Epidermin positive colonies were detected as a zero of growth inhibition of *M. luteus* around the colonies.

Cells were grown on 3% meat extract, 3.8% malt extract, 0.6%  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  and 4.6% NaCl, pH 6.5. According to the transformation used, tetracycline or chloramphenicol was added. After 24 h incubation (37°C, 160 rpm) in 500 ml Erlenmeyer flasks with one extension containing 100 ml medium, the culture both was centrifuged at 10,000 rpm in a Servall centrifuge for 10 min.

Supernatants of liquid transformant cultures were purified by adsorption chromatography (XAD1180, impurities eluted with water/methanol (1:1) and epidermin eluted with methanol/0.1N HCl (9:1); after evaporation the eluate was adjusted with 3N NaOH to pH 3.5 and filled up with water to 10 ml) and detected by HPLC chromatography. The inhibitory activity co-migrated with mature epidermin at 6.75/6.76 min (see Figures 13A and 13B). Untransformed *S. carnosus* culture media treated similarly had no peak in this elution region (6.72 to 6.79 min, Figure 13C). These results clearly confirmed the heterologous epidermin biosynthesis in *S. carnosus* and demonstrated that pTepi4 contains all information necessary for epidermin biosynthesis.

As pTepi4 contains the 13.5kbp BglIII fragment this indicates that the epiY' and epiY'' reading frames are not necessary for the production of epidermin in this system as epiY' lacks a translational start codon and epiY'' is incomplete on this fragment.

#### Example 5

A number of epi<sup>-</sup>mutants of *S. epidermin* Tü3298 were prepared by ethylmethane sulfonate (EMS) mutagenesis. This procedure was carried out according to Miller, J.H., *Experiments in molecular genetics*, Cold Spring Harbor Laboratory; Cold Spring Harbor, N.Y. (1972). The mutants were screened for epidermin production, or lack of epidermin production using the *M. luteus* assay described above. Epi<sup>-</sup>mutants were transferred several times to test their stability. Of the 40 epi<sup>-</sup>mutants isolated, only 10 were stable; the unstable mutants produced epidermin again after several transfers. All stable epi<sup>-</sup>mutants still contained plasmid pTü32 which suffered no deletions or rearrangements as tested by restriction endonuclease analysis. The 10 epi<sup>-</sup>mutants were used for complementation studies.

Various restriction fragments of plasmid pTü32 were cloned in *S. carnosus* to test for heterologous epidermin production. The fragments were inserted into plasmid vectors T181mcs and pCU1 as described above and the various ORFs which were subcloned as shown in Figure 16B.

Cloning was first carried out in *S. carnosus* (by protoplast transformation (Gotz *et al.*, *FEMS Microbiol. Lett.* 40:285-288 (1987)) or *E. coli* (using  $\text{CaCl}_2$ ; Cohen *et al.*, *Proc. Nat. Acad. Sci. USA* 69:2110-2114 (1972)) and then the recombinant plasmids were isolated and transferred into the various *S. epidermis* epi mutants by electroporation (Augustin *et al.*, *FEMS Microbiol. Lett.* 66:203-208 (1990)). Enzymes used for molecular cloning were obtained from Boehringer Mannheim (Mannheim, F.R.G.), BRL (Eggenstein, F.R.G.) or Pharmacia (Sweden). This indirect transformation method was necessary since transformation of *S. epidermin* strains was only successful with circular covalently closed (ccc) plasmids; when ligation products were used, transformants could only be isolated occasionally.

The results of the complementation studies are summarized in Table 1.

Table 1. Epidermin production by non-producing <i>S. epidermidis</i> mutants after transformation with various pTep14 DNA fragments												
Mutant	Complementation with								Mutation locus			
	pTep1 14	pTep1 ABCDQ	pCuep1 ABC	pTep1 AB	pCuep1 A1	pCuep1 A2	pCuep1 CDQ	pCuep1 DQ	pCuep1 Q	pCuep1 B		
EMS 5	+	+	+	+	+	-	-	-	-	-	ep1A	
EMS 6	+	+	+	+	+	-	-	-	-	-	ep1A	
EMS 11	+	+	-	-	-	-	+	+	-	-	ep1D	
EMS 12	+	+	+	-	-	-	+	-	-	-	ep1C	
EMS 13	+	+	+	-	-	-	+	-	-	-	ep1C	
EMS 18	+	+	+	+	-	-	-	-	-	-	ep1B	
EMS 19	+	+	+	-	-	-	+	-	-	-	ep1C	
EMS 33	+	+	+	+	-	-	-	-	-	-	ep1B	
EMS 39	+	+	+	-	-	-	+	-	-	-	ep1C	
EMS 45	+	+	+	+	-	-	-	-	-	-	ep1B	
pCU: Fragments cloned in pCU1; pT: Fragments cloned in pT181mcs + complementation (epidermin production); - no complementation)												

A series of plasmids were constructed which carry various epi genes (A, B, C, D, P and Q) (Figure 16B). Two plasmids pTep14 and pTep1ABCDQ were able to complement all epi<sup>-</sup> mutants. The other constructed plasmids pCuep1ABC, pTep1AB, pCuep1CDQ, pCuep1B, pCuep1A<sub>1</sub>, pCuep1A<sub>2</sub>, pCuep1DQ and pCuep1Q contained the indicated genes.



The various plasmids were able to complement only certain classes of mutants which are classified herein as follows:

EMS 5 and 6 – epiA mutants,  
 EMS 18, 33 and 45 – epiB mutants,  
 5 EMS 12, 13, 19 and 39 – epiC mutants,  
 EMS 11 – epiD mutant.

The results as shown below indicate at least that the four ORFs epiA, B, C and D are required for epidermin biosynthesis.

The plasmid pCUepiA<sub>1</sub> carries the structural gene epiA as the only complete ORF and an additional 10 1400bp upstream and 602bp downstream, the latter encoding 190 amino acids of the epiB N-terminus. Transformation using pCUepiA<sub>1</sub> resulted in the complementation of the epidermin mutants EMS 5 and 6 identifying them as epiA mutants. The smaller epiA-containing Scal fragment cloned in both orientations in pCUepiA<sub>2</sub> failed to complement the epi<sup>-</sup> mutants as the epiA promoter was cut by this enzyme.

pCUepiB carries a BstN1 fragment containing the complete epiB and an upstream region of 100bp 15 which includes 75bp of the 3' terminus of epiA; the epiA promoter is missing. Transformation with pCUepiB failed to complement any *S. epidermis* mutant to epidermin production, indicating that epiB lacks its own promoter and is very likely co-transcribed from the epiA promoter.

This is in agreement with the results obtained with pTepiAB (Figure 16B; Table 1) which contains epiA 20 promoter and the complete epiA and B genes and the use of which complements both the epiA and epiB mutants.

Plasmid pCUepiCDQ was able to complement both epiC and epiD mutants and plasmid pCUepiDQ was only able to complement the epiD mutant (Table 1). The complementation was independent of the orientation of the cloned DNA fragment. These results show that both epiC and epiD possess their own promoters.

#### Example 6

The epiA mutated pTü32 derivatives were isolated from EMS 5 and 6 and the respective epiA ORFs were sequenced. Both plasmids had point mutations within epiA; in the EMS 5 plasmid the codon AGT 30 (Ser<sup>3</sup>) was changed to AAT (Asn<sup>3</sup>) and in the EMS 6 plasmid the codon GGA (Gly<sup>10</sup>) was changed to GAA (Gln<sup>10</sup>); both these mutations were located at crucial sites within the unmodified epidermin.

#### Example 7

35 An epiB (on a BstN1-fragment) was put under the control of the promoter on plasmid pPS4 (Figure 17). The resulting plasmid pPS4epiB was able to complement the epiB mutants EMS 18, 33 and 45. A plasmid containing epiB in the opposite orientation did not complement the mutations. This also establishes that pCUepiB was unable to complement any of the EMS mutants, because the epiA promoter is missing.

#### Example 8

As described above, the presence of pTepi4 (Figure 16A) resulted in epidermin biosynthesis in *S. carnosus*; however, the presence of pTepiABCDQ did not. The minimum size of DNA required which leads to heterologous epidermin expression in *S. carnosus* was determined by complementing *S. carnosus* – 45 (pTepiABCDQ) with distally located DNA fragments (Figure 18). Transformation of *S. carnosus* – (pTepiABCDQ) with plasmids pCA44-90, pCA44-91 and pCA44-92 led to epidermin production, pCA44-92 containing the complete epiQ and epiP ORFs consisted of the smallest DNA fragment able to complement epidermin production. These results indicate that the epidermin biosynthetic genes are clustered within an 8kb DNA fragment containing the six ORFs; epiA, B, C, D, Q and P and that no other 50 genes are involved in epidermin biosynthesis.

In these examples staphylococcal plasmid DNA was prepared by the cleaved lysate method (Makino *et al.*, *J. Mol. Biol.* 190:37-44 (1986)). Cells were lysed by the addition of lysostaphin (8 µg/ml) and the DNA was isolated by CsCl-centrifugation. *E. coli* supercoiled plasmid DNA was prepared by the modified alkaline lysis method (Birnboim *et al.*, *Nucl. Acid Res.* 7:1513-1518 (1979)).

55 The DNA sequence of the PCR-amplified epiA-containing fragment and the two mutated epiA regions of the *S. epidermis* mutants, EMS 5 and 6, was determined by double-stranded DNA sequencing using the dideoxy procedure (McMaster *et al.*, *Proc. Natl. Acad. Sci. USA* 74:4835-4839 (1977)), the "sequence" list of Pharmacia and (α-<sup>35</sup>S)-dATP from Amersham. Primers used for DNA sequencing and

PCR amplification were synthesized using the DNA-synthesizer of Applied Biosystems. The sequences of the two primers for PCR amplification of epiA are as follows:

- a) 5' - GGGTTTTAGG(TA)ATCCTTTTAAATAATTTTATAGGAG - 3'
- b) 5' - CCTCAAATTAAGACG(A)GAT(G)CCTCTATTGAAGCCC - 3'

Primer a) binds in front of the RBS of epiA and primer b) after the epiA stop codon. These bases indicated by bold letters represent (shown in brackets) used to create BamHI sites in front and at the end of epiA; the epiA promoter is absent in the amplified DNA fragment.

For determination of the DNA sequence of the mutated epiA in the mutants EMS 5 and 6, plasmid pTü32 was isolated and the DNA region was amplified by PCR using another set of DNA primers binding upstream of the postulated epiA promoter region (5' - GGTGTTGGTTATTTTCC - 3') and downstream of the stop codon (5' - CCTCAAATTAAGACAGAGCCTC - 3'); the DNA sequence of epiA is also shown in Schnell *et al.*, *Nature (Lond.)* 333:276 - 278 (1988).

#### Example 9

The epi D gene was isolated from the plasmid pTepi 14, multiplied by PCR amplification and cloned into the StuI-restriction site of vector pIH902 (New England, Biolabs) by "blunt end" ligation, with the result that the epi D gene is fused without any intervening base pairs immediately at the Factor Xa-cleavage site of vector pIH902, which was then transformed into *E. coli*.

Cultivation of the *E. coli* resulted in expression of the enzyme Epi D fused to the Maltose binding protein of *E. coli*. The resulting fusion protein was purified by affinity chromatography on Amylose column material.

It was found that the enzyme epiD could be cleaved from the fusion protein in low yield by means of Factor Xa. A modification of the amino acid sequence at the cleavage region will enable the cleavage rate to be improved.

The fusion protein was sequenced at the DNA level from the fusion position to the 3' end of epiD. The epiD sequence corresponded to the wild type sequence of *S. epidermis*.

Plasmid pCA44 is deposited in Staphylococcus carnosus TM 300 at the DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-3300 Braunschweig, Germany, under No. 6863, the deposit being dated 23rd December 1991.

Plasmid pPS4 is deposited in Staphylococcus carnosus TM 300 under No. 6864 at the same depositary, deposit being dated 23rd December 1991.

#### Claims

1. A recombinant DNA molecule having a sequence corresponding to one or more DNA sequences contained in a BglII fragment of the 54 kbp episomal element pTü32 from *S. epidermis* and which codes for at least one protein having Epi B, Epi C, Epi D, Epi P or Epi Q enzymatic activity; or a DNA molecule which is capable of hybridizing to the aforesaid BglII fragment and which codes for at least one protein having one of the aforesaid enzymatic activities.
2. A recombinant DNA molecule according to claim 1, which encodes the protein Epi B, Epi C, Epi D, Epi P and/or Epi Q having the amino acid sequence(s) set forth in Figure 9.
3. A plasmid comprising a DNA molecule according to claims 1 or 2 under the control of a promoter regulator sequence coding for a protein having Epi B, Epi C, Epi D, Epi P or Epi Q activity but wherein one or more of the DNA sequences coding for the other said proteins or Epi A are absent.
4. A protein as defined in claim 1.
5. The protein Epi B, Epi C, Epi D, Epi P or Epi Q in the absence of impurities with which it is normally associated.
6. A method of preparing Epi B, Epi C, Epi D, Epi P or Epi Q, which comprises inserting a DNA sequence as defined in claim 1 or claim 2 into a plasmid vector such that it is under the control of a promoter regulator, inserting the resulting plasmid vector into a suitable host, culturing said host so that the protein is expressed, and isolating the protein.

7. A method of producing a protein having at least one of the structural features of a lantibiotic which comprises inserting a DNA sequence coding for a predetermined amino acid sequence in a vector plasmid such that it is under the control of a regulator promoter, transforming the resulting plasmid vector into a suitable host and cultivating the host so as to express the said DNA and isolating the protein, wherein the host is also transformed by a DNA sequence or sequences comprising functionally operable genes coding for epi B, C, D, P or Q or a variant thereof having epi B, C, D, P or Q activity, which genes are expressed during the said cultivation of the host so that the resulting protein has at least one of the structural features of a lantibiotic.
8. A method according to claim 7, wherein the DNA sequence coding for the predetermined amino acid sequence and the genes coding for Epi B, C, D, P or Q or variants are contained in the same plasmid vector which is used to transform the host.
9. A method according to claim 7 or 8 wherein the said DNA sequence contains or is inserted immediately downstream of a DNA sequence coding for the pre-peptide sequence -30 to -1 of pre-epidermin.
10. A fusion protein comprising one of Epi B, C, D, P or Q and an auxiliary protein.
11. A fusion protein wherein one of Epi B, C, D, P or Q is fused to an auxiliary protein such that the junction between the Epi protein and the auxiliary protein can be cleaved by an enzyme.
12. A fusion protein according to claim 10, wherein said auxiliary protein facilitates secretion of the fusion protein from a selected host.
13. A fusion protein according to claim 10, wherein the auxiliary protein facilitates purification by affinity chromatography.
14. A fusion protein according to claim 10 in which the auxiliary protein is the Maltose binding protein from E.coli.
15. A DNA sequence encoding a fusion protein according to claim 10.



FIG. 1 (1/2)

1  
|  
TTTAAACTTTATATCATTAATATATGTTTAGGAAAGTAGAAGAAATTACACTTTTGTAAATTTTCTGAATATACATA  
am

100  
|  
GTATTTATTTTGGGGAGTACTAAATAATAATTGAAAGGGTTTATATCCTTTTAAATAAATTTTLAGGAGTGTTT

200  
|  
AAA ATG GAA GCA GTA AAA GAA AAA AAT GAT CTT TTT AAT CTT GAT GTT AAA GTT AAT GCA  
M E A V K E K N D L F N L D V K V N A  
-30  
|  
-20  
|  
.

FIG. 1 (2/2)

```

AAA GAA TCT AAC GAT TCA GGA GCT GAA CCA AGA ATT GCT AGT AAA TTT ATA TGT ACT CCT
K E S N D S G A E P R I A S K F I C T P
      |
      -10
      -1 +1

      300
GGA TGT GCA AAA ACA GGT AGT TTT AAC AGT TAT TGT TGT TAATTCAGAAGAATTAGATTGCCAGGG
G C A K T G S F N S Y C C OC
      |
      +10
      +20

      400
CITCAATAGAGGCTCTCTTAATTTGAGGTGAAATAGAAATTGGATAATATATTTTCCATCGAATATATATATGCT
      am

```

FIG. 2A





FIG. 2B










FIG. 3

FIG. 7



Unusual amino acids found in lanthionine peptide antibiotics  
 ("lantibiotics") derived from protein proantibiotics



meso-lanthionine, (2S,3S,6R)-3-methyl- S-(2-(7)-aminovinyl)-D-  
 meso-Lan, D-Ala S-Ala lanthionine, 3-MeLan, cysteine, D-Cys(Avi)  
 D-Abu S-Ala





FIG.5 (2/2)

$\beta$ -hydroxyaspartic acid,  
 Asp( $\beta$ -OH)







FIG. 6

FIG. 7A

EMS 5 plus pCuGal (Gallidermin)




ESTD	RT	AREA	TYPE	CAL #	AMOUNT
	0.73	8.4107E+07	1SBH		0.000
	0.88	434710	DTBB		0.000
	1.01	3.7223E+07	SHH		0.000
	1.29	4978700	SHH		0.000
	1.38	5.3775E+07	ISHH		0.000
	1.53	349830	TBB		0.000
	2.78	343360	TPB		0.000
	3.78	444590	TBY		0.000
	4.03	218110	TYV		0.000
	7.54	408470	TYB	1	11.519
	9.63	132570	TBP		0.000

TOTAL AREA = 1.8242E+08  
 MIN FACTOR = 1.0000E+00

FIG. 7B

Gallidermin- Standard





ESTD

RT	AREA	TYPE	CAL #	AMOUNT
0.80	111200	YH		0.000
0.87	1.0928E+07	SHB		0.000
0.99	153190	DTBB		0.000
5.92	156570	PY		0.000
6.36	967060	YY		0.000
7.15	580800	PY		0.000
7.54	7492100	YB	1	211.280
8.65	212540	BB		0.000
9.61	413430	PY		0.000
9.68	256920	D YY		0.000
9.94	255140	I YH		0.000

TOTAL AREA = 2.1527E+07

MIN FACTOR = 1.0000E+00

FIG.8





## FIG. 9 (1/11)

BglII 20 40  
 AGATCTTGTGTTATATAACTAAACAAATTTCTCCATTTCGTATTTAGAAAATTGACT  
 D Q T I Y S F L N R W E Y K S F Q S

60 80 100 120  
 TTTATCAAGTTTATCCAAATATATATTTCCAGTATATTCTGTATTTAACCCAGCTAATATATTT  
 D L K K D L Y I N G T Y E T N L G A L I N

140 160 180  
 AATAATGTACTTTTCCACACCCACTTTCACCTATAATATTGTAGATATAACCTTTATGAAGAT  
 L L T S K G C G S E G I I N Y I Y G K H L D

200 220 240  
 CCAAACCTTATAGAATTTATTATTTGTTTATTGTCTTTTGTGAAGTTCAAATCATTATTTCCAT  
 L S I S N I I Q K N D K T F N L D N I E M

260 280 300  
 TTTTGAACAAAGTTATTGTAAGTTGTTTAAATAGTTAATACCTCTTCTGGTTCTTTATTATT  
 K Q V F N N Y T T K I T L V E E P E K N I

320 340 360  
 TTTAAAATTCTATCTGAAGATCCAATTGCTCGTTGTAAGTTCCGTTCCAATAAGATGTAATAGATA  
 K L I R D S S G I A R Q V E T W Y S T I S V

380 400 420 440  
 CTATTGGATTAATAATTTGAAATAAATATAAAACATAAGCAAACATATCTCCGCTTTTCATCAT  
 I P N I I Q E L Y L V Y A F M D G S K M M

460 480 500  
 ATTATTTTCCATTAAGTAATAACCCAAAAATAAAATACCAAAAATGTTAATAAATAGAATTAAG  
 N N E H L Y Y G L F L I G F I N I F L I L

520 540 560  
 TTCATAATTGGTTTCGAAAAAAGATAATACTTTGATCTTATGTAAGTCTATATCGAATATATTTT  
 N M I P E F F S L V K I K H L E I D F I N K

580 600 620  
 TTAATAGGGTATAGTTTTTTTATTTTTTCGATATTATATGTAAGTTTAAAGTTTTTATTAATTTTAT  
 L L T Y N K I K E I N Y T S L T K I L K I

640 660 680  
 TGTAAGATAATCTATTACTATAATAAGAAGATAATTTAGCAGTAGCTTCTTGAGATTTACTTGAT  
 T S L R N S Y Y S S L K A T A E Q S K S S

700 720 740 760  
 ACTCTTTTCATTATATTTTCTATAGGTAGTATTACAATTATCAATATAGGTAATGTACACACTA  
 V R K M I N G I P L I V I I L I P L T C V L

## FIG. 9 (2/11)

780 800 820  
 AATATAATGTCAAGGTTTTGTTAATTATATATAAAAAATATTAGTGATACTATAACTGAAAATAA  
 Y L T L T K N I I Y L F I L S V I V S F L  
 oc N Y I F I N T I S Y S F I F

840 860 880  
 ATTCTACAGAAAAACTCTAGTTATGTTTCATAGTATCGTTTACTAACCTACTAGTTAAGTTACT  
 N am  
 E V S F V R T I N M T D N V L R S T L N S

900 920 940  
 TGCTGAGTTTTTTAAGTGAAAACTATAAGGTAACCTTTATCACTTTATTCCATGTAACACTTCTA  
 A S N K L H F S Y P L K I V K N W T V S R

960 980 1000  
 ATGTTTTGTATTATTTTTTGACCTATATATCCAAGAATATAAGTAGAAACACCAGAAAATATTA  
 I N Q I I K Q G I Y G L I Y T S V G S F I L

1020 1040 1060 1080  
 AAGTCAGACCAAAACATATAATAATGATTACAATTTTATCTGTTGATAAGCTAGATTTGTTTAA  
 T L G F C I I I I V I K D T S L S S K N L

1100 1120 1140  
 GGCATTTCTAATTATTAAAGGAATGTATAATGAAAACTAGTTCCAATCAAACCTAAATATTAGT  
 A N R I I L P I Y L S F S T G I L S F I L

1160 1180 1200  
 CCAATACTTAAAAGTAGAGTGTTAGGTTTGGTTATTTTCCATAAATCATATAGACCTTTGATAA  
 G I S L L L T N P K T I K W L D Y L G K I I

S/D 1240 1260  
 TATCATCACCTTTTAAACTTTTATATCATTAATATAATGTTTAGGAAAAGTAGAAGAAAATTACA  
 D D G K L S < epiY

IR 1280 1300 1320  
 CTTTTGTAATTTTCTGAATATACATAGTATTTATTTTGGGGGAGTACTAAAATAATAATTGAAA

1340 IR 1360 S/D 1380 epiA > 1400  
 AGGGTTTTTATAATCCTTTTAAATAAATTTTAGGAGTGTTTAAAATGGAAGCAGTAAAAGAAAA  
 M E A V K E K

1420 1440 1460  
 AAATGATCTTTTTAATCTTGATGTAAAGTTAATGCAAAGAATCTAACGATTCAGGAGCTGAA  
 N D L F N L D V K V N A K E S N D S G A E

1480 1500 1520  
 CCAAGAATTGCTAGTAAATTTATATGTACTCCTGGATGTGCAAAAACAGGTAGTTTAAACAGTT  
 P R I A S K F I C T P G C A K T G S F N S

1540 1560 1580  
 ATTGTTGTTAATTCAGAAGAATTAGATTGGCAGGGCTTCAATAGAGGCTCTGTCTTAATTTTGA  
 Y C C oc epiB >

## FIG. 9 (3/11)

S/D1600 1620 1640  
 GGTGAAATAGAATTGGATAATATATTTGTTCCATCGAATATATATATGGTAAGAACTCCTATAT  
 G E I E L D N I F V P S N I Y M V R T P I

1660 1680 1700 1720  
 TTTCAATTGAATTATATAATCAATTCTTAAATCTGACAATATAGATTATGACTTAATTTTACA  
 F S I E L Y N Q F L K S D N I D Y D L I L Q

1740 1760 1780  
 AAACGATATTTTAAAGAATCTATAATGACAACGACATATAATCTTTATCAAAGTATTGGCAAA  
 N D I F K E S I M T T T Y N L Y Q S I G K

1800 1820 1840  
 ATAGACTGGGAAAAGGATAATAAAAAACCAGAAATGTAAAAGAAAGTTTATTAAATATCTCA  
 I D W E K D N K K T R N V K E S L L K Y L

1860 1880 1900  
 TAAGAATGAGTACTAGAAGTACACCATATGGAATGCTAAGCGGTGTAGCTTTAGGGGAATTTAG  
 I R M S T R S T P Y G M L S G V A L G E F S

1920 1940 1960  
 TGAAAATAATAATATTTAAATTAAGGACTCTTCGTTTCATAAAAAAGATGTAAAAATAGATGGG  
 E N N N I K I K D S S F H K K D V K I D G

1980 2000 2020 2040  
 CAATGGTTATATAAATTAGTCCATTATTTAGAAAGCGATTACACATATTATAAAGACAGTTTGT  
 Q W L Y K L V H Y L E S D Y T Y Y K D S F

2060 2080 2100  
 TCATATGGAATCAACAAAATTATATTTATAACAATCGTTTATATTTAGATAATAATTCATCAAT  
 V I W N Q Q N Y I Y N N R L Y L D N N S S I

2120 2140 2160  
 CACTGAAAATAAAAGAAATGATGTATTATCTGTCAAATACAATTCTATATTAGTGTATTATACAT  
 T E N K R N D V L S V K Y N S I L V F I H

EcoRI 2180 2200 2220  
 GAGAATTCTAAAAAAATATTACTTATGAAGAACTTGTACAATTGATATCTAGTAAGTACAGTA  
 E N S K K N I T Y E E L V Q L I S S K Y S

2240 2260 2280  
 TAGAAAATAAAGAAGAAGTAAAAGTATTTGTTCAAGAACTCATAAATAAAGAAATTATATTTTC  
 I E N K E E V K V F V Q E L I N K E I I F S

2300 2320 2340 2360  
 TGATTTGAGACCTACATTAGAGAATAAAAATCCTTTAGATTACATTATTAATAGTTTAAATCCA  
 D L R P T L E N K N P L D Y I I N S L N P

2380 2400 2420  
 AAAAATAGTTTAGTTGGAACACTTATTAATATTTCTAATGAAATTACAAAATATTCTAAAATGC  
 K N S L V G T L I N I S N E I T K Y S K M

## FIG. 9 (4/11)

2440 2460 2480  
 CTTTAGGAAAAGGAGAATATAAATATTTAGATATTGTTAATTTAATGTCACAATTATTTGTTTC  
 P L G K G E Y K Y L D I V N L M S Q L F V S

2500 2520 2540  
 TAAAACTATTTGCAAATAGATACCTATATAGATTATTCAAGAAATGAATTAAAACAAAGTTTA  
 K N Y L Q I D T Y I D Y S R N E L K Q S L

2560 2580 2600  
 GCTGATAATATTAGTGAAGCAGCATATATTCTCTGGTTATTATCTCCTAATCATTTTGGTACAA  
 A D N I S E A A Y I L W L L S P N H F G T

2620 2640 2660 2680  
 AAACCTATTAGGAATTATCACGAATTTTTTATGGATAAATATGGATTTGAACAACTAGTAAATTT  
 K T I R N Y H E F F M D K Y G F E Q L V N L

2700 2720 2740  
 AAAGCAATTGCTCTCAGATATAAATGGATTTGGCTATCCCCAAAAAGACAGTTATAGTTTTTCT  
 K Q L L S D I N G F G Y P K K D S Y S F S

2760 2780 2800  
 AATAACATTGCATTTTTTAAAAGAAAAGTATTTGCTTGCAATTCAAATAACAGCCATATTGAAA  
 N N I A F L K E K Y L L A I Q N N S H I E

2820 2840 2860  
 TAACAGAAAACGACGTTAAAATTTAGAAAAGAATAATACAGTTTCTAAAATCAATGCGCCTGT  
 I T E N D V K N L E K N N T V S K I N A P V

2880 2900 2920  
 TTCAACTGAAATATATAGTGAGATATATTTTGGAAATTCAATAAAAGGTTATGAGGATTTTGCC  
 S T E I Y S E I Y F G N S I K G Y E D F A

2940 2960 2980 3000  
 GTGATAAGTCCAATATTAGGATCTTTTAATGCCGGTGCAACTTTTGGGAAGGTTTACGGGAAATT  
 V I S P I L G S F N A G A T F G R F T G N

3020 3040 3060  
 TCAATATAAAGAAAAAAATCAATTACAAAAAGAAATAGTGCATCATTACAATAATTACATGAA  
 F N I K K K N Q L Q K E I V H H Y N N Y M N

3080 3100 3120  
 TGAAAATGGTTTAGAAATAAGCCAATTAAATGAAGGTCCTCTTAACCTCAAGAAATGTAAATATT  
 E N D L E I S Q L N E A P L N S R N V N I

3140 3160 3180  
 TTGAATAATAATAGAATATATAATACTTGTTTAAATTTAAATTTACCTAAAAGTGATATAGATA  
 L N N N R I Y N T C L N L N L P K S D I D

3200 3220 3240  
 TAAATGACATATTTATTGGAGCTACATTTAACAACTTTATCTATATTCTGAAAAACATGATTC  
 I N D I F I G A T F N K L Y L Y S E K H D S



## FIG. 9 (5/11)

3260 3280 3300 3320  
 AAGAATTGTATTCGTATCTAATTCAATGTTTAATTATGAGTTTGGATCTGAATTATACAAATTT  
 R I V F V S N S M F N Y E F G S E L Y K F

3340 3360 3380  
 TTAAGAGAAATTTCAATTTGAAAAACAAAATTTATACAACCTATAACTGAAGAAGGCATTGACT  
 L R E I S F E K T K F I Q P I T E E G I D

3400 3420 3440  
 CATTACCTTTTTGTCCAAGAATTATTTATAAAAATATTATTTTAAAACCAGCTACTTGGAAAAT  
 S L P F C P R I I Y K N I I L K P A T W K I

3460 3480 3500  
 AAATTCAGAAATGTTTTCTGAAACTGAAAATTGGTTAAATAGGTTTCGCAACTATTAGAGAAAAA  
 N S E M F S E T E N W L N R F A T I R E K

3520 3540 3560  
 TGGCATATTCCAAAGATGTAATTATTGCTTTTGGAGATAATCGATTGCTATTAAATTTATTAA  
 W H I P K D V I I A F G D N R L L L N L L

3580 3600 3620 3640  
 ATGACAAGCATCTCATTATACTAAAAAAGAACTAAAAAACATGGTAGGATTCGAATATTAGA  
 N D K H L I I L K K E L K K H G R I R I L E

HindIII 3660 3680 3700  
 AAGCTTTATCAATGAATCTAATAATGAGAGAATGTTAGAAATTGTTACGCCATTATATAAAAAA  
 S F I N E S N N E R M L E I V T P L Y K K

3720 3740 3760  
 ACTAGTTTAAAAGAACAATCTTTCATTATACCTAAAAATAGAAATAAGCACTTCAATAATCTTA  
 T S L K E Q S F I I P K N R N K H F N N L

3780 3800 3820  
 AAGATTGGTTTTCAATTCATTTAAGTATTCCTAAAACATACCAAGATAATTTTATTCAAGATTA  
 K D W F S I H L S I P K T Y Q D N F I Q D Y

3840 3860 3880  
 TCTATTACCATTTATAACGGAATTAAAAGTTAATAATTTTATTAAATAAATTTTTTTTACATAAAA  
 L L P F I T E L K V N N F I N K F F Y I K

3900 3920 3940 3960  
 TTAAAGAAGATGAAGATTTTATAAAATTAAGATTATTAAGAGAAGATGAAGATTATTCTCAAA  
 F K E D E D F I K L R L L R E D E D Y S Q

3980 4000 4020  
 TTTATTCTTTCATAAAAAATTGGAAGATTATTGCTTATTAAATAGTGAATTATATGACTATTC  
 I Y S F I K N W K D Y C L L N S E L Y D Y S

4040 4060 4080  
 TATAGTTGATTATGTTTCCTGAAGTATATAGATATGGTGGTCCACACGTAATTGAAGATATTGAG  
 I V D Y V P E V Y R Y G G P H V I E D I E

## FIG. 9 (6/11)

4100 4120 4140  
 AATTTTATGTATGATAGTCTATTATCAATAAATATAATACAATCAGAGTTCAAATTCCAA  
 N F F M Y D S L L S I N I I Q S E F K I P

4160 4180 4200  
 AAGAATTATCGTTGCTATATCAATAGATTTTTATTAGATTATTAGAAATTAATAAAAGTGA  
 K E F I V A I S I D F L L D Y L E I N K S E

4220 4240 4260 4280  
 GAAAGAAGAAATTTTAATTAATAATGCGGAAGATTTATATCGTAGTAATGACATAAGAGAATAT  
 K E E I L I N N A E D L Y R S N D I R E Y

4300 4320 4340  
 AAAAATTTATTAGCTAAACTTACCAATCCTAAAAATGACTATGAAATTTTAAAAAAGAATTC  
 K N L L A K L T N P K N D Y E I L K K E F

4360 4380 4400  
 CGAATCTTCATGAATTTCTATTTAATAAAATTAGTATTTTAGAAAATCTTAAAAAGACACTACA  
 P N L H E F L F N K I S I L E N L K K T L Q

HindIII S/D epic > 4460  
 AAAAAGCTTATATACTTCACGTTCTAGGATAATTGGCAGTTTATACACATGCGTTGTAATAGA  
 K S L Y T S R S R I I G S F I H M R C N R  
 L A V L Y T C V V I E

4480 4500 4520  
 ATATTCGGTATTAATCCTGAAAAAGAAAAATTTGTTTTATCTATTTTAAATGAAATTACAAAA  
 I F G I N P E K E K F V L S I F N E I T K  
 Y S V L I L K K K N L F Y L F L M K L Q K

4540 4560 4580 4600  
 CTAAGAAATATTGGGATGGTTGTGATTAATATTAATAACATTAAAAAATTTTAGAAAATAAAA  
 T K K Y W D G C D oc oc oc  
 L K N I G M V V I N I N N I K K I L E N K

4620 4640 4660  
 TCACCTTTTGTCTGACATTGAAAAAGCTACATATATTATAGAAAATCAAAGTGAGTATTGGGA  
 I T F L S D I E K A T Y I I E N Q S E Y W D

4680 4700 4720  
 TCCTTATACTCTATCTCATGGTTATCCAGGTATAATACTTTTTTAAAGCGCATCAGAAAAAGTA  
 P Y T L S H G Y P G I I L F L S A S E K V

4740 4760 4780  
 TTTCATAAAGATTTAGAAAAAGTAATACATCAATATATTAGAAAAGTAGGCCCTTATTAGAAA  
 F H K D L E K V I H Q Y I R K L G P Y L E

4800 4820 4840  
 GTGGTATTGATGGATTTTCACTTTTTAGTGGTCTTTCCGGAATTGGATTTGCGCTAGACATTGC  
 S G I D G F S L F S G L S G I G F A L D I A

## FIG. 9 (7/11)

4860 4880 4900 4920  
 GTCTGATAAACAGTACTCTTATCAAAGTATCTTAGAACAAATTGATAATTTACTTGTTCAATAT  
 S D K Q Y S Y Q S I L E Q I D N L L V Q Y

4940 4960 4980  
 GTTTTTGATTTTTTAAATAACGATGCATTGGAAGTAACCCCTACTAACTATGATATAATACAAG  
 V F D F L N N D A L E V T P T N Y D I I Q

5000 5020 5040  
 GATTTTCTGGTATAGGAAGGTACTTGTTAAATAGAATATCGTATAATTATAATGCAAAAAAAGC  
 G F S G V G R Y L L N R I S Y N Y N A K K A

5060 5080 5100  
 ATTAAAGCATATACTTAATTACTTCAAAACAATTCATTACTCTAAAGACAATTGGTTAGTTTCA  
 L K H I L N Y F K T I H Y S K D N W L V S

5120 5140 5160  
 AATGAACATCAATTTTTAGATATAGATAAGCAAAATTTTCCGTCAGGAAATATAAATTTAGGAT  
 N E H Q F L D I D K Q N F P S G N I N L G

5180 5200 5220 5240  
 TAGCGCATGGTATTTTAGGTCCTCTATCATTAAACAGCTTTGAGTAAAATGAATGGGATTGAAAT  
 L A H G I L G P L S L T A L S K M N G I E I

5260 5280 EcoRI  
 CGAAGGCCATGAAGAGTTTTTACAAGACTTCACTTCATTTTTTGCTCAAACCTGAATTCAAAAAT  
 E G H E E F L Q D F T S F L L K P E F K N

5320 5340 5360  
 AATAATGAATGGTTCGATCGCTATGATATATTAGAAAATTATATACCTAATTATTCGTCAGAA  
 N N E W F D R Y D I L E N Y I P N Y S V R

5380 5400 5420  
 ACGGTTGGTGTTACGGTGATACAGGGATTATGAATACATTACTTTTGTCTGGTAAAGCCTTAA  
 N G W C Y G D T G I M N T L L L S G K A L N

5440 5460 5480  
 TAATGAAGGCTTAATTAAAATGTCTAAAAATATTTTAATTAACATAATAGATAAGAATAATGAT  
 N E G L I K M S K N I L I N I I D K N N D

5500 5520 5540 5560  
 GATTTAATCAGTCCAACCTTCTGTACGGACTAGCATCGCACTTAACCATTATTCATCAAGCGA  
 D L I S P T F C H G L A S H L T I I H Q A

5580 5600 5620  
 ATAAATTCTTTAATCTATCTCAAGTAAGCACATATATCGATACCATTGTCAGAAAAATTATTAG  
 N K F F N L S Q V S T Y I D T I V R K I I S

5640 5660 5680  
 TCATTATTCTGAAGAAAGTAGTTTTATGTTCCAAGACATAGAGTACTCATACGGACAAAAAATT  
 H Y S E E S S F M F Q D I E Y S Y G Q K I

## FIG. 9 (8/11)

5700 EcoRI 5720 5740  
 TATAAAAACAAAGTGGGAATTCTAGAGGGTGAATTAGGTGTTCTTTTAGCTTTACTAGATTATA  
 Y K N K V G I L E G E L G V L L A L L D Y  
 5760 5780 5800 S/D  
 TTGATACACAAAACCAATCAAGGAAAAATTGGAAAAATATGTTTTTAATAACATAATAGGAGGA  
 I D T Q N Q S R K N W K N M F L I T oc  
 5820 epiD > 5840 5860 5880  
 ATAAGATATGTATGGAAAATTATTGATATGCGCTACAGCATCGATAAATGTAATTAATATTAAT  
 M Y G K K L L C A T A S I N V I N I N  
 5900 5920 5940  
 CACTACATAGTTGAGTTAAAGCAACATTTTGATGAAGTTAATATATTATTTAGTCCTAGTAGTA  
 H Y I V E L K Q H F D E V N I L F S P S S  
 5960 5980 6000  
 AAAATTTTATAAATACTGATGTTCTCAAGTTATTTTGTGATAACTTGTACGATGAAATTAAGA  
 K N F I N T D V L K L F C D N L Y D E I K D  
 6020 6040 6060  
 TCCTCTTTTAAATCATATCAATATTGTAGAAAATCATGAATATATTTTAGTATTACCTGCATCA  
 P L L N H I N I V E N H E Y I L V L P A S  
 6080 6100 6120  
 GCAAATACTATTAATAAAATAGCTAATGGTATATGTGATAATCTTTTAACTACTGTATGTTTAA  
 A N T I N K I A N G I C D N L L T T V C L  
EcoRV 6160 6180 6200  
 CCGGATATCAAAAATTATTTATATTTCCAAATATGAACATAAGAATGTGGGGAAATCCATTTT  
 T G Y Q K L F I F P N M N I R M W G N P F L  
 6220 6240 6260  
 ACAAAAAAATATTGATTTACTTAAAAATAATGATGTGAAAGTGTATTCCCCTGATATGAATAAA  
 Q K N I D L L K N N D V K V Y S P D M N K  
 6280 6300 6320  
 TCATTCGAAATATCTAGTGGCCGTTACAAAAACAATATCACAATGCCTAATATTGAAAATGTAC  
 S F E I S S G R Y K N N I T M P N I E N V  
 6340 6360 Terminator 6380  
 TAAATTTTGTATTAAATAACGAAAAAGACCTTTGGATTAACAAAGGTCTTTTCTAATTAAAT  
 L N F V L N N E K R P L D oc  
 oc C L D K R I L I  
 6400 6400 6440  
 TTTATATCCGAGTTTACGTTTCATTAATAATTTCTATCTCTTTACAATTTTTTAAACTATCCCTT  
 K Y G L K R E N I I E I E K C N K L S D R  
 6460 6480 6500 6520  
 AATCGATGGATATATACATTTATTGTATTAGAATCAACAAAGTCTTCTGTATCCCACACTCCCT  
 L R H I Y V N I T N S D V F D E T D W V G K

FIG. 9 (9 / 11)

6540 6560 6580  
 TTTTAAATTCCTCTTTTGATACATATCTTCCAAGATTAATATATAAGCACCGTAGAATTTTAA  
 K L E E K S V Y R G L N I Y L C R L I K L

6600 6620 6640  
 TTCTATATTAGAAAGATTAACATAAGTAATTATTAAACACAAATTGATGGTTTTCAAAGTCTATA  
 E I N S L N V L Y N N F V F Q H N E F D I

6660 6680 6700  
 AAATCATCATTAAACATATTTAATATACTTTTTTATTTTCAATTTAAATTTCTACATAATATTAAAC  
 F D D N V Y K I Y K K I E N L I R C L I L S

6720 6740 6760  
 TTTTGCTTTCATTATTTTTTATAATATATAAATCTATGCCTAAACTATAAAAATAACACTTCCT  
 K S E N N K I I Y L D I G L S Y F Y C K R

6780 6800 6820 6840  
 ACTATAGCTAGTATTACCTGTTATTATAACTATTGGAATTTTTCCTATAAATTTCTTTTAAAAAC  
 S Y S T N G T I I V I P I K G I F E K L F

6860 6880 6900  
 GTATAATACTCATCAAACCTTTTCATACACAATTATAAAAATTTGGGTCTATATTTGAAGAATTAA  
 T Y Y E D F K E Y V I I F N P D I N S S N I

6920 6940 6960  
 TTGTAATTCCTTCTATCTAATTCTAAAATACTTTCAATAAGAATAGAATCTACCTCACCGACAAT  
 T I R R D L E L I S E I L I S D V E G V I

6980 S/D 7000 7020  
 ATTAATAGAAATCATTTTATTCCCTTCATTCTTTAAGTAATTTGTATACGTCTAGTTTTCCATT  
 N I S I M < •piQ •p E K L L K Y V D L K G N

7040 7060 7080  
 ACCATAATGTTTTTATCCATATATTTTTCTTTTTCTATCCCTTTTTTCTTAAATAACTCTATA  
 G Y H K K D M Y K E K E I G K K K F L E I

7100 7120 7140 7160  
 GCTGTTTCGGGTTGGTCTTTTAATTGATACTTATCAATTTCTAGTGCTAAAGCTCCAGAAACCT  
 A T E P Q D K L Q Y K D I E L A L A G S V K

7180 7200 7220  
 TGGGTGCAGCAAGTGATGTCCCTGATTGATATATGTATCTTCCATTAGAAGAAGTACTTAAAC  
 P A A L S T G S Q Y I Y R G N S S T S L V

7240 7260 7280  
 ACTTTGTTTTTGCATATATCCTTTTTCTAACCAAGCATCTTTTCCATACTTATCTAAAAGTTTA  
 S Q K Q M Y G K E L W A D K G Y K D L L K

7300 7320 7340  
 TAAGAACCTCCTATCGTCATTAAATCTATAAAATTTATTTCCATAATTAGAAAACCTCAGAAATAT  
 Y S G G I T M L D I F N N G Y N S F E S I Y



## FIG. 9 (10/11)

7360 Ba~~HH~~I 7380 7400  
 AATCATTATCATCGATGGATCCTACAGTCATAACATTATTTAGATTTGCTGGGCTATCATATAC  
 D N D D I S G V T M V N N L N A P S D Y V  
 7420 7440 7460 7480  
 CTTTTTTGATGTTTTAGAAATTTAGATTTCTTTTTTTTATTTATTTCTTTTACTTTTTTTTACATTG  
 K K S T K S N L N R K K N I E K-V K K V N  
 7500 7520 7540  
 ATACCGTCATTACCCACAGCTGCAACAACAATACTACCTTTTTTTTGGAGCATAGTTTATAGCTT  
 I G D N G V A A V V I S G K K Q A Y N I A K  
 7560 7580 7600  
 TCTGTAGTGCATCGTAATCAACTTTTTTCATCATCTCTTAATTTTTTTTTTATTTTGATTATCTTT  
 Q L A D Y D V K E D D R L K K K N Q N D K  
 7620 7640 7660  
 AATTAAATAATTTCTAAACTAACGTTGATTACATCATTGTCATCATTTGCTGCATCAATAATT  
 I L Y N G L S V N I V D N D D N A A D I I  
 7680 7700 7720  
 CCTTTAGATACCCAAAGCATTTCACCTTTTCTTTGAGCCAAATACTCGGTATACATTCATCTCTA  
 G K S V W L M E S K K S G F V R Y V N M E V  
 7740 7760 7780 7800  
 CTCCAGGGTTTACACCTTTTAAATTACCGTTTGCTCCTATTGTCCTGCTACTAATGTACCATG  
 G P N V G K L N G N A G I Q G A V L T G H  
 7820 7840 7860  
 ATTCAATTTATCTTCTTCAAAATTTTTATTTCTGATTCATCGTTTTTCGCTACCTCTAAAACCA  
 N L K D E E F N K N G S E D N E S G R F G  
 7880 7900 7920  
 TTTTtaggCACTTCATTAACTATCTTATTTATACTCTTTAAATCTGTATGACTACTATTACAC  
 N K P V E N V I K N I S K L D T H S S N V G  
 7940 7960 7980  
 CAGAATCTACTAAAGCAACTTTTGCTTTTTTTTCTATCTGGACTTAGCTTATAACTTTTACCTTC  
 S D V L A V K A K K R D P S L K Y S K G E  
 8000 8020 8040  
 ATTTGTTATTTTTTCGCATATCCCATTTGTCTGTCAAATAAATCATGGCTGCCATTTTTTTTATTA  
 N T I K R M D W Q R D F L D H S G N K K N  
 8060 8080 8100 8120  
 TTTAAATTTTTTCTGTCTTTACAGATTTTCAACTACACAAGTGGAACAGGTAGGATTACAA  
 N L N K G T K V S K E V V C T S C T P N V F  
 8140 8160 8180  
 ACTTGACGTTTTTATTACTCTTTATTAGTGAATTTAATTTTGATTGCTAGTTTAAATTTGTGC  
 K V N K N S K I L S N L K S K S T K I Q A

# FIG. 9 (11/11)

8200 HindIII 8220 8240  
TGTATGTAGTTCAGGAATTTTATAAGTTAACTCGATATTTTTTTGTTTAATGGATTCTTTAAAA  
T H L E P I K Y T L E I N K Q K I S E K F

8260 8280 8300  
GTTTTGTCATTATCATATTCAACACTATAATAACTTAATTCTTCATTTAGTGAACCTTCCAAAAG  
T K A N D Y E V S Y Y S L E E N L S S G F A

8320 8340 8360  
CATACTCATTTTGCAAAAAAACTAATGACAATATTAAAAAAACAATGAAAAATTTAAATTTGTT  
Y E N Q L F V L S L I L F V I F F K F K N

8380 S/D 8400 8420 8440  
CATATAGCACCTCTAACATATTATTTATATTAAACATTAATTTAACACTTATGTTTTTACTTTT  
M < epiP

8460 8480 8500  
TTATTTATATTATCTTTAATAATGTTCTGTTGCAAGATGAAAAATACGAGGTATCAAAGTACCG

8520 8540 8560  
ATACAGCGAGTATTACACTCAATTAATTAATAATAAAATATGTTGTGATTAAAATTTATTTTAT

8580 8600 KpaII  
AAAAGTATGGGCAATTTATTATTATTCAAGTTAAAACAAAGAGTCCGGGACATAAAGTTTCAGC

8640 8660 8680  
CTCTTCGTCCTAATTACCAAAAACTTACTCCAAAATCCTTTTTTTAGATTGGTTTTTTCTAATT

8700  
TTTT




FIG. 11 (1/2)

Active site I: \*

EPIP	130	EGKSYKLS	PD	RR	KK	AK	VA	LV	DS	GV	NS	SS	HT	DL	KS	IN	KI	VE	NP	170																			
SUBSI	119	APALHS	Q	GY	T	G	SN	K	V	AV	ID	S	G	ID	SS	HP	DL	N	VR	GG	AS	F	V	PS	159														
ISPI	31	APEM	WA	KG	V	KG	KN	IK	VA	LV	D	T	G	C	D	T	S	H	P	D	L	KN	Q	I	IG	C	KN	FS	71										
SUMYTV	19	QAPQ	AW	D	I	A	E	G	S	G	A	K	I	A	I	V	D	T	G	V	Q	S	N	H	P	D	L	A	G	K	V	V	G	G	W	D	F	V	59

.....

## Active site II:

```

*
EPIP 170 PKNGFRGSENDESGNKNFEEDKLNHGTLVAGQIGANGNLKGVNPGVEMNVY 220
      .. :::::: :: :::: :::: :::: :::: :::: :::: ::::
SUBSI 146 PDLNVRGGASFVPSETNPYQDCSSHGTHVAGTIAALNNSICVLGVSPSASL 196
      ::::::: :: :::: :::: :::: :::: :::: :::: ::::
ISPI 163 QIIGCKNFSDDDGCKEDAI SDYNHGCHGTHVAGTIAANDSNGGIAGVAPEASL 113
      :::: ::::
SUMYTV 67 NGNGHGCHGTHCAGIAAAVTNNST 87

```

## Active site III:

```
*  
EPIP      380 YMQKQSVLSTSSNGRYIYQSGTSLAAPKVSCALALEIDKYQ   420  
           :. :: :. : .:::.::.: :. :.  
SUBSI     305 MAPGVSIQSTLPGGTYCAYNGTSMATPHVAGAAALILSKHP   345  
           ....: :. : .:::.::.: :. :.  
ISPI      224 VAPGENILSTLPNKKYCKLTGTSMAPHVSGALAL-IKSVE    263  
           . :: ... : .:::.::.: :. :.  
SUMYTV    203 AAPGSWIYSTPTSTYASLSGTSMATPHVAGVAGLLASQGR   243  
*
```



FIG. 12

	10	20	30	40	50	60
EPIQ	MISINIVGEVDSILIESILELDRRITINSSNIDPNFIIVYEKFEDEYYTFLKEFICKIPIV					
						...
PHOB	VLEQNGCFQPVAEADYDSAVNQLNEPWPDLILLDWMLPGCGSIQFIKHLKRESYTRDIPVV					
	30	40	50	60	70	80
	70	80	90	100	110	
EPIQ	IITGNTSYSRKCYFYSGLGIDLVIKKNESKSLILCRILNEIKKYIKYVNDDEFID-----F					
	..... . . . . : .					
PHOB	MLTARGEEDRVRGLETGADDYITKPFSPKELV-ARIKAVMRRIISPMAVEEVIEMQGLSL					
	90	100	110	120	130	
	120	130	140	150	160	170
EPIQ	E--NHQVFVFNYYLVNLSNIELKILRCLYINLGRYVSKEELKKGVDTEDFVDSNTINVYI					
	. . . . . : .					
PHOB	DPTSHRVMAGEEPLMGPTFEFKLLHFFMTHPERVYSREQLLNHVWGTVVYVEDRTVDVHI					
	150	160	170	180	190	
	180	190	200			
EPIQ	HRLRDSLKNCKEIEIINE-RKLGKILIRKDL					
	.: : : : : . . . . : : : : .					
PHOB	RRLRKALEPGGHDHVMVQTVRGTYRFSTRF					
	200	210	220			

FIG. 13




FIG. 14




FIG. 17




FIG. 15




FIG. 16





FIG. 18





(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 543 195 A3**

(12)

**EUROPEAN PATENT APPLICATION**(21) Application number: **92118598.9**

(51) Int. Cl.<sup>5</sup>: **C12N 15/52, C12N 15/62,  
C12P 21/02, C07K 3/08,  
C07K 13/00, //C12N15/31**

(22) Date of filing: **30.10.92**(30) Priority: **31.10.91 US 784234**

(43) Date of publication of application:  
**26.05.93 Bulletin 93/21**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE**

(88) Date of deferred publication of the search report:  
**08.06.94 Bulletin 94/23**

(71) Applicant: **Dr. Karl Thomae GmbH**  
**D-88397 Biberach(DE)**

(72) Inventor: **Entian, Karl-Dieter, Dr.**  
**Oberurseler Strasse 43**  
**W-6370 Oberursel/Ts. 5(DE)**  
Inventor: **Götz, Friedrich, Dr.**  
**Beim Herbstenhof 31**  
**W-7400 Tübingen(DE)**  
Inventor: **Schnell, Norbert, Dr.**  
**Seidmannsdorfer Strasse 148**  
**W-8630 Coburg(DE)**  
Inventor: **Augustin, Johannes, Dr.**

**Viktor-Renner Strasse 59**  
**W-7400 Tübingen(DE)**  
Inventor: **Engelke, Germar, Dr.**  
**Grüneburgweg 82**  
**W-6000 Frankfurt/Main(DE)**  
Inventor: **Rosenstein, Ralf, Dr.**  
**Corinthstrasse 6**  
**W-7410 Reutlingen 22(DE)**  
Inventor: **Kaletta, Cortina, Dr.**  
**Seehauser Strasse 14**  
**W-8000 München 70(DE)**  
Inventor: **Klein, Cora, Dr.**  
**Bernardstrasse 26**  
**W-6050 Offenbach(DE)**  
Inventor: **Wieland, Bernd, Dr.**  
**Burkhardstrasse 34**  
**W-7407 Rottenburg(DE)**  
Inventor: **Kupke, Thomas, Dr.**  
**Ludwigstrasse 12**  
**W-7400 Tübingen(DE)**  
Inventor: **Jung, Günther, Dr.**  
**Ob der Grafenhalde 5**  
**W-7400 Tübingen(DE)**  
Inventor: **Kellner, Roland, Dr.**  
**Tuchbleich-Strasse 12**  
**W-6148 Heppenheim(DE)**

(54) **Biosynthetic process for the preparation of proteins.**

(57) A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described.

Also disclosed are recombinant DNA molecules

which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.

**EP 0 543 195 A3**



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 92 11 8598

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
A	EP-A-0 342 658 (DR. KARL THOMAE GMBH) * page 2, line 1 - line 4 * * page 2, line 20 - line 45 * * page 4, line 16 - line 36; examples 1,2 * ---	1-3, 7-9	C12N15/52 C12N15/62 C12P21/02 C07K3/08 C07K13/00 //C12N15/31
A	NATURE vol. 333, no. 6170, 19 May 1988, LONDON GB pages 276 - 278 NORBERT SCHNELL ET AL. 'Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings' * abstract * * page 276, right column, paragraph 3 * ---	1, 7	
P, X	JOURNAL OF BACTERIOLOGY vol. 174, no. 16, August 1992 pages 5354 - 5361 THOMAS KUPKE ET AL. 'Purification and characterization of EpiD, a flavoprotein involved in the biosynthesis of the lantibiotic Epidermin' * abstract * * page 5354, right column, paragraph 3 * * page 5356, right column, paragraph 1 - page 5357, right column, paragraph 1 * * page 5357, right column, paragraph 6 - page 5358, left column, paragraph 1 * * page 5358, right column, paragraph 2 * --- -/--	1-6, 10-15	TECHNICAL FIELDS SEARCHED (Int. Cl. 5)  C12N C12P C07K
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>30 March 1994</b>	Examiner <b>Montero Lopez, B</b>
<b>CATEGORY OF CITED DOCUMENTS</b>  X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document  I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons --- & : member of the same patent family, corresponding document			



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 92 11 8598

DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)												
P, X	EUROPEAN JOURNAL OF BIOCHEMISTRY vol. 204, no. 1, February 1992 pages 57 - 68 N. SCHNELL ET AL. 'Analysis of genes involved in the biosynthesis of lantibiotic epidermin' * abstract * * page 59, right column, paragraph 6 - page 64, left column, paragraph 2; figure 2 * * page 64, right column, paragraph 2 - page 65, right column, paragraph 4 * * page 66, right column, paragraph 2 - page 67, right column, paragraph 1 * ---	1-5, 7-9													
P, X	EUROPEAN JOURNAL OF BIOCHEMISTRY vol. 204, no. 3, March 1992 pages 1149 - 1154 JOHANNES AUGUSTIN ET AL. 'Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis' * abstract * * page 1151, left column, paragraph 1 - page 1152, left column, paragraph 1 * * page 1153, right column, paragraph 2 - page 1154, left column, paragraph 2 * --- -/--	1-4, 7, 8													
The present search report has been drawn up for all claims															
Place of search THE HAGUE		Date of completion of the search 30 March 1994	Examiner Montero Lopez, B												
<table><tr><td>CATEGORY OF CITED DOCUMENTS</td><td></td></tr><tr><td>X : particularly relevant if taken alone</td><td>I : theory or principle underlying the invention</td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td>E : earlier patent document, but published on, or after the filing date</td></tr><tr><td>A : technological background</td><td>D : document cited in the application</td></tr><tr><td>O : non-written disclosure</td><td>L : document cited for other reasons</td></tr><tr><td>P : intermediate document</td><td>A : member of the same patent family, corresponding document</td></tr></table>				CATEGORY OF CITED DOCUMENTS		X : particularly relevant if taken alone	I : theory or principle underlying the invention	Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date	A : technological background	D : document cited in the application	O : non-written disclosure	L : document cited for other reasons	P : intermediate document	A : member of the same patent family, corresponding document
CATEGORY OF CITED DOCUMENTS															
X : particularly relevant if taken alone	I : theory or principle underlying the invention														
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date														
A : technological background	D : document cited in the application														
O : non-written disclosure	L : document cited for other reasons														
P : intermediate document	A : member of the same patent family, corresponding document														

EPO FORM 1503 03.82 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 92 11 8598

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
P,X	PROCEEDINGS OF THE 1ST INTERNATIONAL WORKSHOP ON LANTIBIOTICS. NISIN NOVEL LANTIBIOTICS 1991 pages 277 - 286 JOHANNES AUGUSTIN ET AL. 'Identification of epidermin biosynthetic genes by complementation studies and heterologous expression' * abstract * * page 279, paragraph 4 - page 282, paragraph 2 * * page 283, paragraph 2 - page 284, paragraph 1 *	1-4,7,8
P,X	PROCEEDINGS OF THE 1ST INTERNATIONAL WORKSHOP ON LANTIBIOTICS. NISIN NOVEL LANTIBIOTICS 1991 pages 269 - 276 NORBERT SCHNELL ET AL. 'The operon-like organisation of lantibiotic epidermin biosynthesis genes' * abstract * * page 271, paragraph 2 - page 273, paragraph 1; figure 3 * * page 274, paragraph 2 - paragraph 4 * * page 274, paragraph 6 * * page 275, paragraph 3 *	1,2,4
The present search report has been drawn up for all claims		
Place of search	Date of completion of the search	Examiner
THE HAGUE	30 March 1994	Montero Lopez, B
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons @ : member of the same patent family, corresponding document		

EPO FORM 1503 (01.82) (P04C01)